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Turning Stealth Liposom~s· into ·.Cationic . Liposomes for 
Anticancer Drug Delivery 
Abstract 
by Vijay Gyanani 
University of the Pacific 
2013 
Targeting the anticancer agents sele~ively to cancer cells is desirable to improve the 
efficacy and to reduce the side effects ofanticancer therapy. Previous·Jy reported passive 
tumor targeting by PEGylated lip()s()mes (stealth liposomes) llaye resulted in their higher 
tumor accumulation. However their interaction with cancer cells has been minimal due to 
the steric hindrance of the PEG coating. 
This dis~rtatiort reports two approa¢hes to enhance the interaction of stealth liposomes 
with cancer cells. Firs~ we designed a lipid-hydrazone-PEG conjugate that removes .the 
PEG coating at acidic pH as in the tumor interstitium. However~ such a conjugate was 
highly unstable on shelf. 
Second we developed lipids with imidazole headgroups. Such lipids.· can protonate to 
provide positive charges on liposome surface at lowered pH. Additionally. negatively 
charged PEGylated phospholipids can cluster with the protol}ated imidazole lipids to 
display excess, positive charges on the surface of the liposomes, thus enhancing their 
interiction with negatively charged cancer cells. 
6 
We prepared convertible liposome formulations I, U and III consisting of one ofthe three 
imidazole-based lipids DHI~ DHMI.and DHDMI with estimated pKa values of5.53, 6.2 
and 6.75, respectively. Zeta potential measurement confirmed the increase of positive 
surface.charge of such liposomes at lowered pHs. DSC studies showed that at pH 6.0 
fonnulation r formed two lipid phases, whereas the control Jiposome IV remained a one-
phase system at pHs 7A and 6.0. The interaction of such convertible liposomes with 
negatively charged model liposomes mimicking biomembranes at lowered pH was 
substantiated by 3-4- times increase in average sizes of the mixture of the convertible 
liposomes and the modelliposomes at pH 6.0 compared to pH 7.4. 
The doxorubicin-loaded convertible liposomes show increased cytotoxicity in Bl6Fl0 
(murine melanoma) and Hela cells at pH 6.0 as compared to pH 1A. Liposome III shows 
the highest cell kill at pH 6;0 for both the cells. The control formulation IV showed no 
difference in cytotoxicity at pH 7.4 and 6~0. Uptake of convertible liposome U by 
BJ6FIO cells increased by 57% as the pH was lowered from 7.4 to6.0. 
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Chapter 1: Introduction 
an~er Epidemiology 
ancer is a group of dise~ses cbarac~erized by tincontmlled growth ofabnonnal cells that 
ave a potential to invade other tissues (1,2}. Cancer is a foremost cause of death 
·orldwide which lead .to 7.6 million deaths worldwide (around l3 %of all deaths) i.n 
008 (3). The t{)tal number ofc.feaths due to cancer will continue to rise to an estimated 
~. J million in 2030 (3). Iri United States cancer is the most common cal.lse of death 
. Jcceeded by only heart ,disease~ American cancer society estimates that in 2013- ab<)ot 
80~350 Americans are expected to die of cancer, which acco.uf1ts for 1600 deaths a day 
nd nearly one of every 4. deaths. About 1.660,290 new c:ancer cases are. expected t9 be· 
iagnosed in 2013 (1}. From 1991 to 2006,. the death rate from heart diseases (most 
ommon causeofdeath) declined. to two :thirds but that from cancer declined .much more 
Jowly to 83% despite technological advances in medical and allied health fields (4). 
!his highlights the importance of anticancer Tesearch and warrants the time,. money and. 
1m~rt to~iscovcr novel ways to trea,t cancer. 
~ancer Nomenclature and Pathology 
rhe term ~cancer· is a derived from the Greek word •J<:arkinos' meaning crab (5). Early 
1bseryers s~w spread and persistence ofcancer as crab-like and hence the term (6}. An 
~nonnal growth ofcells forming a lesion or lump is called a 'Neoplasm' or 'Tu~ot'. A 
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widety accepted definition of Neoplasm by Sir Rupert Wittis (Willis, 1952) states ••an 
.!bnonnal mass of tissue~ the growth of which . exceeds· and is uncoordinated with that. of 
normaltissue and persists in the same excessive manner after cessation of stimulus which 
evoked the change". Neoplasm is characterized by its irreversible nature. Tumors can be 
cancerous or non cancerous. Non cancerous tumors, also called benign tumors, are 
limited to certain part of body and are not ominous to the host~ White cancerous tumors 
or malignant tumors de-differentiate from the tissue of origin and invade to other parts of 
the body causing significant damage to the host owing to its uncontrolled growth and 
spread. The development of malignant tumor is a multistep process .comprising of 
initiation, promotion and propagation stages. Initiation of tumor invorves genetic 
, alteration in a single cell leading to abnormal growth (8). During the cell promotion 
stage actively proliferating cell population is generated by the division of the mutated 
cell. Tumor progression continues as the further mutations of the proliferative cell 
population takes place and some of these mutations result in a clone of cells with higher 
growth potential. This clone of cells outnumbers other cells in the tumor in a process 
called 'clonal selection'. The clone. of cells may undergo fr¢quent genetic alterations to 
produce a new clone of cells with higher mutation potential as a result of their ·increasing 
genetic instability. The progression stage is thus a multi step process in that a series of 
· clone of cells with ever increased proliferative capacity and metastatic potential are 
produced (8). 
, It is very important for a pathologist to identify the tumor and classify a tumor as benign 
or malignant. The criteria for the diagnosis of a malignant tumor· include size of primruy 
tumor, the depth of tissue invasion at primaty tumor site, the extent of spread to local 
17 
rmph nodes and presence or absence of distant metastasis (7). The deliverance of 
nticancer therapy depends on the: diagnosis of a malignant tumor. 
:'umor nomenclature describes tumor by the tissue of their origin- epithelial. connective~ 
nuscular or nervous (5). As a general rule; a suffix ~oma• is applied to n¢arly all tumor 
ypes whether benign or malignant and irrespective ofthe histological origin (5) except 
br tumors of hematopoietic and lymphopoietic systems where a suffix •emia~ is used. 
Challenges and Limitations~ of Current Anticancer Therapies 
Current most commonly employed anticancer strategies include sutgery, radiotherapy 
and chemotherapy. Although these anticancer strategies have their own advantages-, there 
are certain limitations associated with them. 
1.1 Ca,neer surgery. Surgery, for instance, may seem to be a convenient option for· 
removing solid twnors; but it should be noted that not all tumors can be :surgically 
removed. If the tumor is sufficiently big so as to impose serious damage on the 
surrounding normal tissue or regular functioning of the organ e.g. nonnal functioning of 
brain including thinking, speaking etc. surgery is not considered as an antitumor strategy. 
Prostrate, ovarian and uterine surgery may cause pennanent damage to fertility, while 
1ung cancer surgery.may cause breathing problems and bre~thlessness. Lung. surgery, in 
some instances, has also been known to affect voice and vocal cord tissues. Oral cancer 
surgecy· pr<Jcedures ·such· as· Glassactomy although ·may not eliminate the.ability to speak 
but speech is not as dear and swallowing may be difficult. On the other hand 
laryngectomy completeTy eliminates regular speaking. Regardless of the above 
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nentioned complications associated with tumor removal t . · · 
· a vanous sttes. surgery itself 
Jas inherent issues. such as infection and local nerve damage. 
L2· Chemotherapy. For treatments su~h as chemotherapy either free drug ('f mo~t 
ikely a combination of drugs is administered in the body. Although chC"mOthcrapy is tm~ 
of the few treatment options for metastasized cancer the- major dr.t\\bad; of 
chemotherapy is its poor selectivity. Since cancer cells originate from normal cells that 
grow out ofcontrol~ anticancer drugs that suppress gro\\th of cancer cells also a fleet the 
growth of no]lilal cells. The poor selectivity of common chemotherapeutic drugs is due 
to the proliferative nature of cancer cells. Not only that the anticancer drugs have toxic 
effects on cancer cells, they also have potential to impose serious damage to ~me 
marrow. gastrointestinal tract and hair follicle (9). To cite a few cxamplr:s: the dose~ 
limiting hematotoxicity including thrombocytopenia and neutropenia are prevalent in 
carboplatin and/or carboplatin in combination with other chemotherapeutic agcnls. Skin 
effects especially keratitis are common side effects of chlor:ambudL Cisp1atin has been 
known to accumulate in the kidney by a transport mediated _process aflcr continu(lUS aod 
prolonged exposure and caqse severe dose dependent tubular and glomerular dysfunction. 
mitochondrial swelling and nuclear paUor in distal nepltron (11 ). Cumulative toxidt~· 
due to Anthracyclines, doxorubicin being a most common example~ may cause 
cardiomyocyte damage and apoptosis due to production of free radicals and acute 
· · ·· · · 1 h hm.. • rditis mvocarditis and acute hcan 
cardtotoxtclty that may me ude arr yt tas. penca , · *· . 
failure. Additionally~ chronic cardiotoxkity associated with anthracydines include 
··b .· cer treatment in particular. 
conditions such as left ventricular dysfuncuon. For reast can 
"1 (CMF).ree:imen has been known 
the cyclophosphamide~ methotrexate and 5-fluorouract . · · -
19 
' cause neutropenia, alopecia and emesis (14). In case of 5-fluorouraciJ .containing 
:gimens e.g. cyclopho$phamide, doxorubicin (Adriamycin), and 5-fluorouracil (CAF) or 
·fluorouracil, doxorubicin, and cyclophosphamide (F AC), mucositis appears to be 
ommon than non fluorouracil regimens like doxorubicin and cyclophosphamide (AC) 
14). It is interesting to note that paclitaxel when administered in higher dose (i.e. 225 
.1glm2) in sequential regimen has shown severe .and recurrent neuromuscular toxic"ity as 
ompared .to lower dose (i.e., 175 mg/m2). 
Jesides aforementioned notable examples of severe .side effects of chemotherapeutic 
1gents, there are cases where patients are beleaguered with side effe-cts that are not 
nalignant but do have a significant effect oil the quality of life and may result in 
:liscontinuation or undue disruption of chemotherapy. Skin diseases are the prominent 
l1110ngst them (16). Common side effects on skin i.e. skin rash, skin dryness. 
hyperpigmentation and on mucosal membrane include Steven Johnson Syndrome and 
toxic epidennic necrolysis are cau-sed by commonly used drugS such as 
Cyclophosphamide, Chlorambucil, Busulfan and Procarbazine. Novel anticancer agents 
such as EGFR inhibitors markedly cause skin dryness and follicular rash which can then 
result in pruritis or other infections (16). The most common ofthe follicular rash is the 
papulo-pustular rash. Other common skin e.ffects such as Erythma and sweUing are 
associated with administration of antimetabolites such as 5~Fiuorouraci1 and capecitabine 
(16). 
In .addition to the poor· selectivity of chemotherapy mentioned hitherto, the other major 
limitation is the development of rnultidrug resistance (MDR) (Fig. 1.1). Cancer cells 
may develop resistance that might begin against a single drug or a group of drugs with 
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similar mechanism of action but may transfonn into cross resistance against other drugs 
with different> targets or mechanism of actions in a process called. multidrug. resistance 
(MDR) (27). MDR leads to growth of ·heterogeneous cancer cells due to mutator 
phenotype as a result of selection of cells that are ·able to gr.ow in the presence of 
chemotherapeutic drug/s (27). Drug resistance in cancer cells is developed either by 
modification in drug target or by enhancement ofthe repair mechanisms of the cells such 
as DNA repair and induction of cytochrome oxidases(27), Additionally, one of the most 
prominent mechanisms ofmulti..drug resistance is the over-expression of ABC binding 
cassette transporters based efflux transporters. The increased effiux transporters· reduce 
the amount of drug to suboptimal 1eveJs in the cells (27). MDR can also develop from 
reduced intracellular uptake of hydrophilic drugs e.g folate analogues • .cisplatin etc. (89). 
Examples for the later are ciaplatin, methotrexate, 5 fluorouracil etc. Funhennore 
inefficiency in apoptotic · cycles ll}ay .lead to · MDR, precisc~ly due to ineffective p53 or 
alterations in ceramide levels. 
bb'od YtiS1M 
·-~~j( ...  
Fig. 1.1 Overexpression of Pgp transporter proteins leading to efflux of drug from the 
cells. (Reproduced from (92)) 
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Of the reasons mentioned above and the fact that chemotherapeutic agents have narrow 
therapeutic index in that there is a small difference in the dose required for an anticancer 
effect and the dose causing significant toxicity, limits the therapeutic implication of 
chemotherapy. Furthermore, the damage to normal cells entails reduction in the dose of 
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he anticancer drug which eventuany leads to inefficient disease control~ drug resistance 
md metastasis. 
1.3 RadiQfherapy. Radiotherapy, another commonly practiced anticancer therapy. 
~mploys the use of high energy X rays for the treatment of cancer. The applications of 
radiotherapy vary from tumor kill to tumor shrinkage to pain. relief. While the side 
effects of an anticancer drug or a combination of drugs are systemic. the .side efTt-cts of 
radiation therapy are more of the local nature (in the proximity of the tumor). Radiation 
side effects on patients are manifested either· as early effects or late ·effects. Early effects 
are mainly skin related effect.~ which include skin erythema and desquamation. Late 
radiation effects include fibrosis~ atrophy, radiation induced blood vessel and ncuronar 
damage. While it is important to note that short term effect-are reversible, late effects are 
either irreversible or aggravate with time. The response manifested as late effects are 
. medi;:tted by inflammatory; stromal, endothelial and parerK:hymal cells. Fibrosis. one of 
the late effects. is characterized by excessive extrncellular matrix and collagen deposition 
in region of irradiated tissues. The early phase offibrogenesis is simi-lar to the·wound 
healing process characterized by initiation of cytokine·cascades essentially marked by 
release oftumour-necrosis factor-a (TNFa),Jnterleukins I and 6 (IL 1 and IL6} and other 
growth factor in the irradiated tissue ( 17). While in a regular wound healing process 
TNFa and connective tissue growth factor (CTGF) downregulate· TNF f3 which is a strong 
fibrotic factor; the wound healing in irradiated tissues continue for years7 which leads to 
fibrosis of tissues (J 7). Al)other aspect. of radiation side effects is the kno""n to be 
affected by the reduced oxygen content (hypoxia) in the tumor environment. lt is 
reported that radiosensitivity of cells is diminished due to hypoxic environment which 
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nduces high J¢vels .of heat shock pt6t~iit in tumor cetlsand also stimulate io.creasein 
.tu.mber of cells with high proliferative capabilities (13). Specifically the increased 
txpression and stabilization of hypoxia inducing factor· HIF 1 a is responsible for the 
jncrea$e in radiotesi~~ce Qf cells~ The HIFt a expression is increased by activation of 
phosphatidylinositol 3-kinase (Pl3K)/Akt/mamma1ian target of rapamycin (mTOR) 
pathway and increased stability of HIP I a by itS interaction. with Heat shock protein 90 
(Hsp 90) (18). 
Tumor Targeting and its Challenges 
As mentioned earlier chemotherapy .and radiotherapy have many side effects and the 
most common reason for chemotherapeutic. side effects is the .non specific, .indiscriminate 
effect on nonnal and tumor cells. The anticancer dtug effect has its basis in fast 
multiplying cancer cell lines, which therefore can affect rapidly dividing nonnal ceJls. It 
is interesting to note that only 5-10% of the drug administered reaches. tumor tissue (25). 
Paul Ehrlich introduced the tenn •magic bullets1 to selectively target a drug. to disease• 
~ausing organisms. Since then a number of targeted drug delivery systems have been 
, develo~. Most of Qle nov¢ld¢g delivery systems developed in the past few decades 
include liposomes, prodrugs, polymer cpnjugates, micelles and dendritic systems. tumor 
.targeting approaches. can be broadly divided .into two categories: Active' and passive 
targeting. 
1.4 Active .targeting. Active targeting exploits phenotypict biochemical and 
morphological differences between nonnal and cancer .cells (26). Most common tumor 
targeting strategy employ biologically specific interactions .such as antigen-antibody or 
24 
ligand· receptor binding for delivering cytotoxic agents locally in the tumor tissue and 
may .involve drug uptake by receptor mediated endocytosis through association of the 
drug or drug carrier molecule with the antigen or ligand (26). Precisely~ tumor targeting 
incorporates tumor specific ligands on nanocaniers/drug conjugates that can bind and 
deliver antiCancer drugs to tumor cells, thereby sparing normal cells. Conversely, antigen 
heterogeneity in cancer cells presents a major limitation to activ.e targeting; .different 
types of cancer or even same type of cancer.at different .developmental stages express 
different pathological and biochemical profiles. Receptor density is also an important 
parameter in active targeting. It is crucial that the number of receptors/targets is over-
expressed in the tumor cells compared to nonnal cells. For example~ a receptor density 
of I 0~ per cell (29) of ErbB2 is required for improved breast cancer therapeutic efficacy. 
Similarly Bcell targeting by liposomes grafted with anti-CD 19 antibody requires a.-CD 19 
density in the range of l 04 - 1 os per cell (28). Atany stage of cancer development down-
regulation or shedding of antigen from cancer cell surface might severely affect 
therapeutic outcome. Shed antigens circulating around cancer cells may compete- for 
binding of the ligand and therefore reduce the binding and internalization of the 
therapeutic agent(29). Furthennore, if the binding.affinity between the targeting ligand 
and its teceptor is too high it wi11 hinder the quantitative uptake of anticancer agent in the 
tumor due to high affinity binding with the first few target cells - a phenomenon known 
as binding-site barrier (29). As an example, Adams et al (30) showed that bio-
distribution of single chain Fv molecuJ~s {SCFv) in SK·OV-3 tumors is regulated by the 
binding affinity of the SCFv molecules to the her2neu receptor overexpressed by the 
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:sneer cells. The excessively high binding affinity of mutant scFv beyond l 0-9 M 
~tateaued the quantity ofscFv distributed in the tumor (30). 
/.4~1 Antibody. and ,Qntibody fragments. As targeting agents, whole antibodies are 
stable in solution but are usually immunogenic and can bind to macrophages via the Fe 
domain, thus increasing their clearance and shortening their circulation half Jives (29). 
To reduce the immunogenicity of antibodies, chimeric or humanized antibodies were 
developed but their· production is very expensive. Addtionally, large antibodies when 
used as targeting moieties for ilan()particles thwart attempts of multivalent decoration on 
the rtanoparticJe. surface due to the steric hindrance. Antibody fragments. on the other 
hand. sucfl. aS. the .Fab or scFv <fontains are mote Spt!cific to their targets but have stability 
issues Md carry less avidity due to their monovarent binding domain. When non~ 
antibody small molecules such as RGD, folate and transferrin are used as the homing 
moiety, the targeting is not exclusive to tumo.- tissues and affect nonnal tissues. Also. 
free folate molecules present in the body .can compete with the forate target ligand for its 
receptor on cancer cell surface (29). 
].4.2 Immunotoxins and · immunoc(}njuglllts. lm.rnunotoxins and lmmunoconjugates. 
although have been recently clinically approved but find limitations for anticancer 
therapies due to their moderate to severe side effects. Immunotoxins are either antibodies 
or antibOdy derived proteins that are linked to. toxins. Patients on immunotoxins as 
anticancer agents have expressed high levels of hepatic transaminase levels; indicating 
localiZation of toxin in liver; Additionally flu·like symptoms and vascular leak syndrome 
have been observed in patients on immunotoxins. Anti B4 blocked ricin have 
demonstrated Human antimouse antibody responses and anti~ticin responses (29). 
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mmunconJugates are similar to immunotoxins except for the c)1oto~ic drug :is linked to 
fie antibody or protein instead of the toxin. Jmmunoconjugates-works on the principal of 
mtigen-antibody binding as mentioned earlier. The major limitation these systems is the 
aumber of drugs linked to antibody. On an average 3-lO molecules of drug have bc.cn 
known to be attached to an antibody molecule without affecting the antibody binding 
affinity (29), e.g. approximately 8 molecules of doxorubicin are coupled w'ith AR96 
antibody (31). lmmunoconjugates have shown limited success due to: l) large number 
of antibodies needed to .deliver therapeutic amount of drug 2) reduced intemali;~.ation of 
drugs 3) suboptimal drug release from the conjugate (29) 4) toxicities induced hy the 
treatment~ e.g. severe gastrointestinal toxicities induced by BR96-Dox.. immunoconjugate 
(Jl). 
1.4.3 lmmunoliposomes. Liposomesare nanometer lipid bilayer vesicles with aqueous 
interiors that can encapsulate hundreds of thousands ()f drug mol~:culcs and thus address 
the issue of limited number ofdrug molecules bound to the antibody or any other ligand. 
thereby reducing the high amount ofimmunoconjugates required to be administered tO 
have sufficient drug at the tumor site. ImmunoJiposomes, are Hposomes with targeting 
antibodies attached to their surface. The high payload ensures very high drug to antibod)· 
ratio. However, the challenges with immunoliposomes are similar to .other acti\'e 
targeting approaches viz .. the decoration of 1arge number of antibody molecutcs on 
liposome surface increases their clearance~ development and production. The 
receptor/antigen density and the avidity of ligand for the receptor/antigen may pose 
· 1· · · · · th ·b·· d. • • b · phe· no·men·on leading to limited tumor mterna u.at10n tssues or e m mg-stte amer . 
penetration and reduced cytotoxic effect on antigen negative cancer cells. 
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1.5 Passive tumor targeting. Passi"·e targeting of nanocarriers does not employ any 
targeting ligand but relies only on the 'Enhanced Permeation and Retention' eflect (Fig. 
1.2) for their accumulation in the tumor tissue and retention in the tumor cells. The 
enhanced penneation of nanocarriers in the tumor occurs due to leaky tumor vasculature 
while the retention of the nanocarrier at the tumor site is due to the dysfunctional 
lymphatic drainage (28). Although the challenges imposed by active targeting e.g. 
antigen heterogeneity, ligand avidity etc are not associated with passive targeting, it has 
certain limitations. The major limitations associated with only liposomal systems will be 
discussed here. 
No~··.··.····. 
Fig. I .2 'Enhanced Permeation and Retention' effect showing the extravasation of 
liposomes in tumor tissue (reproduced from http://www.regulon.orglprofile.html) 
1.5.1 Conventional /iposomes. The first generation liposomal introduced were the 
conventional liposomes (90). Upon intravenous administration conventional liposomes 
are recognized and captured by the reticuloendothelial system (RES). This approach has 
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been exploited in treating. parasitic and microbial infections of the RES. A classiC 
example is Ambisome (ArnB) which delivers amphotericin B. to fungus-infected 
macrophages. However~ conventional !iposomes have miniiJ1al effect beyond cells of 
RES due to extensive blood clearance and short circulation half life·(JS, 36), Semple et 
al (40) reported that cationic Uposomes made of l~.-dioleyl-3-N,N,N­
trimethylaminopropane chloride (DOTMA):DOPC (1 :1 mol mor1) and DOTMA:DOPE 
{1: 1 mol mof1) have a protein bitlding (PB) value in excess of500g protein /mol and are 
cleared rapidly from circulation in mice (40). Inclusion of 50% of the cationic lipid 
DOTMA in the liposome composition results in strcmginteractions with serum protein to 
the extentthat they together form. Clots in plasma ( 4 t). A similar formuJation employing 
DODAC instead of OOTMA with DOPE acquired a PB value of 800 g protein /mol and 
had a circulation half life of only few minutes ( 40). A series of cationicliposomes made 
by oku et al, 1996 (42) have displayed PB values ranging from 400--11 O() g proteins/mol 
of total lipid (40), (42). The results are not surprising considering the fact that majority 
ofplasmaproteins carry negative charges at physiological pH (40). 
Different approaches have been employed to increase the circulation half life of 
Uposomesin vivo~ Papahadjopoulos. and coworkers (39) prepared stericaUy stabilized 
liposomes with hydrogenated phosphotidyl inositol/ phosphatidyl choline/ cholesteror 
(HPIIHPC/chol) which showed a liposome .. assodated doxorubicin half Hfe .of 15.5 hrs 
while conventional fiposomes based on egg-derived phosphatidyl glycerol, phosphatidyl 
choline and cholesterol showed a liposome associated drug half life ofonly l hr · 
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·1.5.2 Stealth Liposomes.. Another strategy to im_prov(lip()sc>rne blood circulation time 
is to coat a hydrophilic polymer such as Polyethylene Glycol (PEG) on the Jiposome 
surface. The mail\ fe~ture of having PE:O gra6ed on the liposome surface is the 
flexibility· which permits a SJ11all percentage of PEG~lipids on the liposome to imp;1rt a: 
stericalJy stabilized hydrophilic shell around the' Hposome. The hydrophilic, sterically 
· stabilized PEG coating reduces adsorption of serum proteins on Uposomes and their 
subsequent Clearance by the R.ES. As the PEG ~ides the surface of liposotne from being 
recognized these liposomes are called 'stealth liposomes'. The drug epirubidn has a 
halftife ofonly 14 min. However, when encapsulated in Stealthliposomes (SL)the half 
life increased dramatically to 1 S hrs. Also, the free epirubicin and its SL encapsulated* 
epirubicin showed more than 200-fold difference in both AUC and in clearan~e (39). 
An example of stealth liposome~ which is now commerciaJly available is 'Ooxil'· 





Pig. J .3 Doxil coated with Polyethylene Glycol (adapted from {94) 
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The protein binding values of PEGylated liposomes are reported to be much lower 
compared to the conventionalliposomes. Semple et al ( 40) reported that liposomes made 
ofDSPC:CH and EPC:CH:DOPA in a lipid mol ratio 55:45 and 35:45:20 had PB values 
of 19 and 46 respectively. When 5% DSPE-PEG were included in above compositions 
the PB values dropped to 7 and 25 respectively ( 40). Du et al ( 46) showed that adhesion 
of erythrocytes, lymphocytes and macrophages onto glass surface coated with 
DPPE!DSPE-PEG liposomes drastically decreased as the DSPE-PEG mol% in such 
liposomes increased from 0 to 1%. However, the rate of decrease slows d0\\11 ac; the PEG 
mol% increases further from I to 5 %. 
Despite the increase in the accumulation of sterically stabilized Jiposomes in the tumor 
vicinity, the steric hindrance of the polymer chains on the liposome surface has posed a 
challenge in the interaction of liposome with tumor cells. Hong et al 1999~ ( 43) reported 
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that the Te (AUCtumor/AUCplasma) ratio of DSPC/CholesteroJ liposomes were 0.87 
compared to0.31 in the PEGylated liposome with 6% DSPE-PEG in mice bearing C26 
tumor. Similar findings were reported by ·Parr et al 1997; (44). where DSPC/Cholesterol 
and DSPC/CholesteroJIPEG-PE liposomes in Lewis Jung model suggesteda Te vaJue of 
0.76and 0.4 respectively. 
The reducedinteraction and bmdin~ ofstericaUy stabilized Jiposomes with· tumor ceUs 
reduces intracellular uptake .of these caniers which causes the therapy to completely rely 
on the slow release of encapsulated drug from the liposome which might be ·suboptimal 
for tumor elimination. 
Strategies of Triggered Release from Liposomes. 
To increase the release of drug from the liposornes various strategies have been 
introduced including external stimuli (ultrasound; light and temperature change) but each 
one of them. have their-own challenges. 
1.6 Triggered release by ultrasound. Ultrasound is a non invasive technique which 
can be focused to target tissues~ can- alter the penneabiJity ofcell membranes and can be 
controlled (47) (48). Acoustically active liposomes (ACL)~ Hposomes that have air 
pockets and are responsive to reduced pressure or ultrasound, prepared by Huang et al 
(47) used ultrasound as the triggering mechanism for calcein release from 
EggPC/DPPEIOPPG/CH liposomes at a molar ratio of 69:8:8:15. Although the calcien 
release was carefidly controltedt the encapsulation efficiency of calcein during lip<>some 
preparation was very low (~ 20%) and the encapsulation and triggered release of 
hydrophobic. drugs remained untested. 
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: 1.7 Triggered release by ligllt. The ligbt·sensitive Jiposomes exploit 
photoisomerzation, photocleavage or photopolymerization of photoresponsive lipids in 
liposome membrane. The majority of photoisomerizable liposomes incorporate. 
azobenzene lipids that isomerizes to cis fonn upon -illuminated by ultraviolet light and 





















Fig. 1.4 (a) Drug release from liposomes by photoisomerization of lipids 
(Reproduced with permission from (49)) 
""'\ 
''""'· 
Conversion to the cis- fonn can destabilize the membrane and release drug contents. 
Although azobenzene derivatives have been extensively studied, retinoyl-phosphoJipids 
(50) and spiropyran, which converts to merocyanine at low wavelength of 365 nm have 
also been reported (51). The major drawback of photo-isomerization is that the 
33 
wavelength required to photo-isomerize the photosensitive lipids is in the lower range 
(lower visible or UV) which has limited penetration in the body. 
The second major strategy of triggering liposomes by light is to incorporate 
photocleavable lipids in the liposomaJ membrane (Fig. 1.4 (b)). Thompson et al (52) 
reported the use of photocleavable lipids derived from plasmologen. Photocleavage is 
enhanced by incorporating photosensitizers such as zinc phthalocyaninet tin 
octabutoxyphthaJocyanine, or bacteriochlorophyll a. into the hydrophobic region of the 
Jiposomal bilayer (42). 
b 
Fig. 1.4 (b) Drug release from liposomes by photocleavage of lipids 
(Reproduced with permission from (49)) 
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Apan from naturally occurring plasmalogen lipids, synthetic photocJeavabte dithiane-
based lipids have been reported (53) (54) to increase the drug release from liposorttes. 
Interestingfy Zhang and coworkers synthesized a DOPE-based photocleavable lipid 
called NVOC-DOPE which upon· illumination by xenon lamp yielded free DOPE and 
subsequent membrane destabilization. 
To date, the .most successful of an the photo-induced triggering mechanisms is the 
plasmalogen based photosensitive liposomes although the sensitization ofphotocleavage 
of -plasmalogen by sensitizers have resulted in production of reactive oxygen species 
which compromises the ,safety in patients. 
A third light-induced drug releasing mechanism is the· photo•polymerization (Fig. lA 
(c)). The polymerization of cross a linking lipid 1,2-bis(l0-(2\4•-hexadienoyloxy)-
decanoyl}·sn-phosphatidylcholine in Hposomes up<>n UV illumination yielded more than 
I 00-fold increase in the release of fluorescent agent (56). The wavelength of the UV 
light can be adjusted by encapsulating pbotos~nsi~izer dyes· that can trigger the 
polymerization of lipids at higher wavelengths of light that are considered biologically 
safe. The incorporation of l, 1'-dioctadecyl-3,3.3',3'• tetramethylindocarbocyanine iodide 
(Oil) dye is one such example (49). 
c 
Fig. 1.4 (c) Drug release from liposomes bypbotopolymerization of lipids 
(Reproduced with pennission from {49)) 
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Although similar to photocleavable triggering strategy in tenns of safe wavelength range. 
the stability ofpolymerizable lipids have not been tested yet (49). 
In a photochemical triggering approach, O.V. Gerasimov et at, who explon.~ photo-
oxidative triggering in Bcbl:DPPlsC Hposomes, suggested that the photo-oxidative 
triggering method is severely limited by the low P<n level in the tumor environment. The 
ineffective photo-oxidation leads to creation of physiologically conducive atmosphere for 
growth of non apoptotic cells due to faulty photo-oxidation of tumor tissues (57). 
1.8 Triggered release by hyperthermia. Yatvin et al {58) in 1978 reponed heat-
triggered release of neomycin from thennosenstive liposomes. An array of 
thennosenstive liposomaJ syStems have since then been developed to increase the drug 
release at the tumor site. The thermo-triggered release approach is multifaceted in that 
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· the application of heat I} enhances vascular penneability and therefore accumulation at 
the wmor site, 2) e~ the release of drug from thennosensitive liposome at the 
, tumor site, 3) probably increases localized blood supply and alter the intracellular uptake 
,: of drugs. Fig. 1.5 aptly illustrates the first two points. 
Fig. 1.5 A) enhanced accumulation ofliposomes by EPR 8) increased pore size of tumor 
vasculature C) increased drug release from the liposomes. (reproduced with permission 
from (59)) 
Traditionally tbennosensitive liposomes have employed lipids that undergo 
conformational change from the trans- form to the gauche- form. (59) at the lipid 
transition temperature, which converts the lipid membrane from the gel phase to the 
liquid crystalline phase of higher fluidity, which in tum enhances the drug leakage from 
the liposome. However the incorporation of purely lipid of lower melting temperature 
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such as DPPC (MP = 41°C) has.shown slow and less amount of drug release. Also. the 
retention of drug molecules during circulation has been challenging. Incorporation of 
lipids .of higher melting temperature such as DSPC (MP = 54°C) to increase packing 
incompatibility and therefore enhance drug release yielded broad peaks in Differential 
Scanning Calorimetry and n~cessitated higher triggering temperature (higher than 43°C) 
which can cause necrosis to nonnal tissues surrounding the tumor tissue. An estimate by 
Mosher.er and coworkers (62) showed that the initiation of necrosis on porcine muscle 
begins after .30 min. of heat application at 40-43°C. Fine tuning the drug release at mild 
hyperthermia conditions (3941°C) while maintaining the sharp melting peak so as to 
ensure efficient drug release in ·1ethal doses remains a challenge for thenno·sensitive 
liposome research. 
Another approach of .preparing thennosensitive liposomes is the incorporation of 
Jysolipids in the. lipid membrane. Lysolipids are lipids that have bulkier head group with 
single acyl chain. These lipids typically fol'IIl micelles at]d the lateral movement of these 
lipids as the temperature approaches transition. results in the accumulation of these lipids 
at pockets which start melting first, thus creating a micelle like curved structure at these 
pockets (Fig. 1.6). 
Lysolipid-\."()Urainjng thermosensitiv«j ··uposome 
Fig 1.6 Traditional and lysolipid containing liposomes. 
(reproduced with permission from (59)) 
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The formation of curved structures releases drug through the pores thus formed. 
Needham and coworkers (63) incorporated 10 % of the lysolipid MPPC in liposomes 
which resulted in reduction in phase transition temperature from 430C to 3940 °C and 
rapid drug release (approx. 500AJ released in 20s heating at 42°C). In general induction of 
lysolipids in liposomes drasticaUy reduces the heating time which in tum reduces the 
possibility of onset of necrosis in surrounding tissues (59). However, the in vivo stabi.lity 
of the lysolipid containing liposomes remains a cbaUenge. Banno and coworkers (65) 
reported that 70 % of the lysolipids were desorped from the liposome surface in vivo 
after one hour of injection and the amount of drug released from the Jiposomes recovered 
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from mice plasma after and 4 hrs of injection was 20% and 50% less. This suggests 
decrease in thermo sensitivity of liposomes after desorption of lysolipids. Sandstrom et 
at (66) demonstrated release of 50 % drug from lysolipid liposomes after I hour of 
injection in vivo. 
The application of heat has been thus fart limited to superficially located tumors with 
regional heating. For localized hyperthennia microwave and radiowave applicator have 
been used ( 64} but the therapeutic depth of the external temperature stimuli is limited to 3 
em. For deep seated tumors microwave and radiofrequency electrodes with expandable 
prongs can be used but this approach remains invasive and is limited to the body area 
where insertion is practical (59). 
Focused ultrasound although has been developed that can control the temperature 
remotely in deeply seated tissues with restricted focal zone but the monitoring of 
temperature still is done by invasion of temperature probe (59). 
1.9 Triggered release by magnetic field from magnetic liposomes. Another strategy 
to triggered drug release is the application of magnetic field. Amstad et aJ. incorporated 
lipid coated iron oxide nanoparticles in the liposome membrane (Fig. 1.7) and showed 
the enhanced release of contents upon application of alternating magnetic field (AMF) 
due to local heating by iron oxide nanoparticles and thereby increase in membrane 
penneability. (68). 
Fig J • 7 Iron oxide nanoparticJes incorporated in lipid membrane. 
(reproduced with permission from (68)) 
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Similar work was done by Babincova et al (69) where increasing concentration of 
ferromagnetic material in the membrane showed increased membrane penneability viz. 
as much as 70 %release of adriamycin at a ferocolloid concentration of J .2 mg Fe/mL 
Another approach to prepare magnetic liposomes is to encapsulate magnetite particles in 
the Hposomes which can then be directed to the tumor site by placing a magnet in the 
tumor vicinity externally. Nobuto et al (70), showed that the application of steady 
magnetic field of 0.4 tesla around tumor implanted limb of Syrian male hamsters 
increased the dox. concentration in tumor by 3 to 4 fold after intravenous administration 
of the magnetic liposomes. In the similar limb tumor model design, (71) instead of 
externally placing a magnet, magnet or non magnetic alloy was placed in the center of the 
tumor. Intravenously administered, adriamycin-loaded magnetic Uposomes showed 
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~ignificant antitumor activity and greater accumulation in tumor vasculature under 
,magnetic force compared to magnetic liposomes without magnetic torce (non magnetic 
alloy). 
ln one example, Hposomes loaded with Tc 99 albumin resulted 25-fold increase in 
;radioactivity in the left kidney of the rats under study where SmCo magnet was implanted 
compared to the right kidney without the magnet (72). 
: In an interesting study (73) RGD coated magenetic liposomes were first uptaken by 
•· monocytes and neutrophils and then magnetically directed to brain for the delivery of the 
model drug diclofenac sodium. 
Furthermore, Magnetoliposomes prepared with bacterial magnetic particles containing 
• cis-diamminedicbloroplatinum (II) (CDDP) have been observed (74) to have 1.7 fold 
concentration at tumor site than the one ones prepared by artificial magnetic materiaL 
Conclusion 
Commonly employed anticancer therapies and common tumor targeting strategies were 
reviewed and their limitations and challenges were discussed. Although active targeting 
employs specific ligand to enhance the drug delivery, antigen heterogeneity, high cost of 
production~ immunogenicity and insufficient stability remain as its pressing challenges. 
Passive targeting by liposomes is an attractive approach to bypass these issues but the 
release of the cargo drug needs to be optimized. Because the drop of pH is involved in 
the interstitial space of many solid tumors, it serves as an attractive approach to trigger 
the release of anticancer drugs from liposome. Liposomes that respond to low pH (pH-
sensitive liposomes) will be discussed in the following chapters. 
Chapter 2: Add Labile Linkers for the Design of pH-Sensitive Lipids and 
Liposomes 
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The pH gradients in the tumor tissues present an interesting trigger. The pH in the tumor 
interstitium is 6.5 to 7.0 while the pH of the tumor core may be as low as 6.0. Once the 
fommlation is endocytosed it meets even lower pH environment in the 
endosomal/lysosomal pathways where the pH is 2~3 units lower than in the blood 
circulation. Such lower pH can be exploited for either increased intracellular uptake of 
liposomes in the tumor tissue or destabilization of the liposome membrane for drug 
release intracellularly. 
One attractive approach of designing pH-sensitive liposomes is to incorporate pHw 
cleavable lipids in the Jiposomes. pH-cleavable lipids can be constructe-d by 
incorporating an acid labile linker betWeen the hydrophilic head and lipophilic tail of the 
lipid. The acidic environment cata:lyzes the hydrolysis of the lipid. An ideal liposomal 
formulation made of pH-cleavable lipids will be relatively stable at physiological pH and 
will destabilize upon cleavage of pH sensitive lipid either in the tumor environment or in 
the endosome/lysosome compartment of the cancer cells to release drug contents. Cordes 
and bull (76) have described the mechanism and catillysis of acetals. ketals and 
orthoesters. A number of acid-labile lipid structures have been designed to study their 
enhanced cytotoxic effects. The hydrolysis mechanism and pH sensitivity of such lipids 
are discussed m this section according to their acid-labile linkers. 
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Acetal.Linker 
Acetal Jinker (Fig. 2.1) is an acid-labile linker where one carbon is attached to an alkyl 
group; a hydrogen atom and two alkoxy groups~ The acidic hydrolysis oftheacetallinker 





























Scheme 2.1 Acidic hydrolysis of Acetal 
Song and Hollingsworth (77) designed pH-sensitive acetaJ·based glycolipid (Fig. 2.2) 
and measured its pH sensitivity in ethanol. While 0.01 %addition of DCJ started acetal 
cleavage which completed in 5 hours, addition of acetic acid from I to 20% did not show 
any ·significant acetal .cleavage after 14 hours of observation under NMR. The pH 
sensitivity of the acetal based glycolipid remains to be tested in vivo. 
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Fig. 2.2 pH-sensitive acetal based glycolipid 
' Asokan et al in 2004 (78) designed a ' his-detergent' BD2 (Fig. l.J) by cross linking two 
single chain tertiary amine detergents through an acetal linker. The pKa of headgroup 
, was detennined to be 6.37 ± 0.36. Liposomes prepared by 75 mol% of BD2 and 25 mol% 
: of phosphatidyl choline demonstrated a hydrolysis half life of 3 brs at pH .5.0 and showed 
' complete hydrolysis at pH 4.0 after 6 hrs. The design of 'his-detergent' irreversibly 
. . 
, cleaves two single chain lipids which results in disruption of Jiposomes and release of 
drug content(Scheme l.l). 
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OH'YN............._,OxQ~N~OH 
OH . OH 
Fig. 2.3 Chemical Structure of BD2 lipid 
S~heme 2.2.Mechanism ofacidc~y~hydrolysisBD2lipid. 
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The Hposomesnutde ofBD2 were shown to enhance the intracellular deliveryofTexas 
red-labeled oligonucleotides (TR·ON) and ON-705 compared to liposome with BDl 
lipids (bis-detergent without pH labile linker}. 
;Vinyl Ether Linker 
··Vinyl ether (Fig. 2~4) is another linker which is relatively stable ar neutral. pH and 
hydrolyzes in acidic environment (Scheme 2.3). 
Fig. 2.4 VinylEther Linkage 
'·_::,_ ·. ·: -~ 
+ 
·.· ... 




... ·.. ·. 
.:··.·· · ... · .. 
ROH .. · ··=-=== 
Scheme 2.3 Hydrolysis mechanism ofVinylEther under acidic conditions 
. . 
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Thompson and associates (79) have designed a series of Hpids (Fig. 2.5) with vinyl ether 
linkages betWeen the lipid tail and p0iar head group. · They prepared liposomes with 
DOPE and pH-sensitive vinyl ether lipids. The mol % ofOOPE was 90 %or higher, the 
high percentage of DOPE helps the transition of liposome from lamellar to hexagonal 
phase as the head group of vinyl ether pB-sensi.tive lipid cleaves from the lipid. The 
conversion of the liposorne from lamellar to the hexagonal phase is dependent upon the 
kinetics of acidic hydrolysis of vinyl ether group. The best fonnulation that could 
achieve content release as much as 60"/o when calcein was uSed as a model dye was ST 
352/DOPE in the molar ratio 5/95 after:::::. 4~ hours at pH 4.5. The slow release of 
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~ontents from the lipO.s<>me suggests slow rate of hydfQiysis of pH-sensitive vinyl ether 
lipids ai:td therefore slower transition from lamellar to hexagonal phase; 
(n=4S) 
(n= ll4) 
0 0 0 
· MeOfv-00NJ-.o""'v0~o)lN.A.v<>-:"f-01 




Fig. 25 Vinyl Ether lipids prepared by Thomson and Associates 
· Thompson and assoch1tes .(80) in 1998,.synthesized vinyl ether based pH-sensitive lipids 
(DPPfsC) (Scheme l.4) where vinyl ether was linked between each of the two 
hydrophobic tails and the rest of the lipid molecule~ Although the liposomcs made of 
DPPisC were very stable at pH 7.4 the calcein release kinetics of these liposomes 
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Scheme 2.4 Acid catalyzed hydrolysis ofDPPisC 
Table. 2.1 pH Dependence of 500/o Release Time of Calcein 






The calcein release studies from liposomes made of pure DPPisC at 37°C indicate that 
the time required to release 50% of calcein was::: 4 bat pH 5.3 while it took ::::: 29 h for 
50% caleein release at pH 6.3. Slow calcein release at lowered pH coupled with the fact 
that .no calcein release was detected after 48 hrs of incubation at .pH 7.4 suggest high 
stability of liposomes and less pH sertsitivity ofthe vinyl ether lipids. However, less pH 
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sensitivity at lower pH's reduce the release ofencapsu1ated contents from the Hposomes. 
,-Another study by bergstrcJ.nd et al, (82) employed. DHCh~MPEG 5000 (Scheme 2.5) 
lipids where vinyl ether ~as linked between PEG 5000 and hydrogenate(f cholesterol. 
i The leakage percent ofD}lCh-MPEG 5000!DOPE Hposomes at am.olar ratio of 1:99 was 
about 22 % after 20 hrs ofincubation at pH 4.5. Also, even 5 days of incubation of the 
conjugate at that pB could not completely hydrolyze the conjugate. 
OH 
DHCho MPEGSOOO 
Scheme. 2.5 Acid Hydrolysis ofDHCho-MPEG5000 
: Ortho Ester 
• Orthoester is a more pH-sensitive linker than vinyl ether and is also found to be relatively 
· stable at physiological pH. The acid-triggered hydrolysis of orthoester involves a 
: stabilized diaJkoxy carbonium ion (Scheme 2.6) that further degrade to an alcohol and an 
ester compound (81). 
HlO,slow 
Scheme 2.6 Hydrolysis mechanism of Orthoester 
Guo and Szoka synthesized a pH sensitive 'POD~ lipid with a diort:hoester linker (Fig 
2.6) and incoporatedit into liposomes. (Hydrolysis Se.heme 2.7) 
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. . . . 
Pig. 2.6 Structure of the 'POD' lipid 
~0 OH 
R,-()H + X . + R2-0H 
HO 0~ 
0 
Scheme. 2.7 Acidic hydrolysis oforthoester based lipid 
The incorporation of POD and DOPE in a ratio of 1/9 in liposome membrane stabilizes 
the liposome at physiological pH but at low-pH POD hydrolyzes to shed off the PEG 
coating to wnvert the DOPE-rich liposome membrane to a hexagonal phase. 
The stability of I 0 mol % of POD incorporated into liposomes at alkaline pH 8.5 was 
about 2 weeks. In vivo studies on POD/DOPE liposomes suggested a half life of200 min 
(83) while the half life. ofDSPE-PEGIOOPE lipoSomes \\'35 ~ 295 min. Stability studies 
of POD conjugate suggested that it remained intact for 3 hours at 3 7°C while complete 
5.4 
: hydrolysis was observed at pH 5 within 1 hour (81 ). The POD liposomes resulted in 
: extensive content release and aggreagation at pH 5*6 (81 ). The release of contents from 
the liposomes contains two phases: a lag phase when the contents slowly leaks through 
the liposome membranes followed by a burst phase when sufficient POD hydrolysis 
triggers the lamellar-to-inverted hexagonal , phase change of the liposomes to quickly 
release most of the contents. 
The POD has also been exploited in intracellular delivery of plasmid DNA (8 1 ). 
Stabilized plasmid-lipid particles (SPLP) composed of OOT AP~ OOPE and plamid DNA 
and 1.3 mol% POD resulted in liposome collapse within 110 min. at pH 5.3 whereas the 
pH*insensitive lip()somes witboutPOD remained stable at 1owered pH. 
Instead ofdiorthoester, masson et al (84) designed five and six membered ring orthoester 
based lipids (Fig. 2. 7) and incorporated them into lipoplexes. The conjugates were stable 
for 8everal days at pH 7.5 but the long tenn stability of lipoplexes composed of the pH 
sensitive orthoester lipids was not determined. 
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Fig. 2.7 Ortho ester lipids designed by Masson et aL 
Hydrazone Linker 
Hydrazone presentS another linker (Fig .. 2~8} that has been exploited by researchers for 
pH-triggered drug/gene delivery. 
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Fig.2 ,8<Chemical structureofhy.drazone tinker. 
Aissaoui .et al (95) synthesized a series of cationic guanidinium based lipids- (Fig. 2.9) 
' where acylhydrazone iinker was used to link head group with a steroid. lipid tail. All .the 
lipids were demonstrated to undergo. acid-catalyzed hydrolysis; It was observed that 
unsatlltated compoUnds BGBH,chotest-.4:0enone and BGTH·cholest•4~enone showed 
s]o\Yer hydrolysis kinetics with halftives t.9 and 2j days at pH 4.8 than the saturated 
8GBU~cholestimone and BGTH~cho)estanone compound~Lwith halflives oft.2 and 1.3 
days reSpectively. The lipoplexes composed of bis-guanidinium bis~(2~aminoethyl)arnine 
hydrazone (BGBH)-chcdest;,.4-eri()P¢/l)NI\ m¢diated efficient gene transfection in 




H'N 2 \..._ . 
11NH .· 0 
HN ~ .- -~ U ~ 
N- ........., ---~-N ( . . 
NH 
HN~NHz , 3. CH~OzH 1-21, BGTH.,Cholestanone 
i-22, BGTH:.Cholest-4--enone 
Figure 2.9 Chemical structures of gliarii(liniurihbased cationiclipids. 
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Shedding of PEG Coating by Hydrolysis of Hydrazone Linker 
. eased on the review of pH~sensitive linkers we propose a strategy to improve 
intracellular uptake ofliposomes by shedding the PEG coating that hinders the .interaction 
ofliposomes with the cell surface in the V1~inity of tumor. The PEG coating can be 
removed ~Y placing a hydrozone linker between lipid tails and polar head group~ Whil~ 
hydrated PE(J . ~oating around the liposome st~rfac~ hinders the hydrophobic: interactions 
with serum proteins and immun~ .ceJls in blood circulation, the removal of the PEG 
coating will lead to increased interaction of the liposomes with cancer cells at the acidic 
tumor interstitium. 
One C()tnmon feature of all cells is ne,gatively charged celt surface. The presence. of 
negatively charged lipids such as .phosphatidylserine (PS) and phosphatidyJ inositol {PI) 
impart negative charge on the cell surfac~. Vance and Steenbergen in 2005 (85), 
determined. that approximately 15 % of.PS and PI were found in rat liver .cell membrane. 
Additionaly the ~ell surface has an abundance of extracellular matrix (ECM} that contains 
proteogJycans and glycosaminogtycans which provide a majority {)f negative charges at 
the cell surface (Fig. 2.10). Additionally, tumor surface charge was found .to be even 
more . rtegative than normal cells (88). The glycosaminoglycans in the ECM include 
heparan sulf~te. chondroitin sulfate and hyaluronic acid. 
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Fig. 2.1 0 ExttaceUuraf matrix over cells 
Work of Mounkes et al (86) and Mislick et al (87) established that heparin!heparan 
sulfate and chondroitin sulfate play a crucial rc)ie in intracellular uptake of cationic 
• lipoplexes. 
Based on the aforementioned, we propose a pH .. sensitive liposomal system that will act 
as a stealth liposome at physiological pH and convert to cationic liposome at lowered pH 




(pH 6 .!\-7.0) 
CeU 
Fig. 2.11 Concept of design of hydrazone based pH -sensitive liposome 
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To achieve the pH triggering a novel PEG-lipid conjugate containing hydrazone linker 
can be introduced in the liposome membrane as mentioned earlier. The hydrazone tinker 
is expected to hydrolyze at Iow·pH environment to shed off the PEG coating and leave a 
hydrazide lipid which cmt acquire positive charges on liposome surface in the weakly 




lxcessive positively charged lipid (elg J)()TAP)to overcome the limited mol% ofPEG~ 
~pid conjugates that Call be incorprirated into the liposaine membrane. 
Rt 
R1 R3 
\ H /(") .. 
N-N\. . C_,_O-H I :.' \ 
R') ' + R$ 
- H 
I 
\ . . 
+ N-NH,. I -
Ri 
Scheme 2.8 Acid HydrolysiS of Hydrazone 
·. ·.·. 
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2.1 Materials and methods. 1,2:..Di..O-hexadecyl-rac-glycerol (DHG) was purchased 
from Bachem. Ethyl B~oace~te. sodium hydride (60% dispersion in mineral oil). 
hydrazine hydrate (80%), Iodobenzene diacetate {BAlli), 2,2,6,6-Tetramethylpiperidine-
1-oxyl-4-amino-4-carboxylic acid (TEMPO) were acquired from Fisher Scientific. 
Polyehtylene glycol 2000 monomethyl ether was obtained from Sigma Aldrich. All other 
organic solvents were purchased either from Sigma, Fisher or VWR. 
2.2 Synthesis 
2.2.1 Synthesif of ethyl-2-(2,3-bis(hexadecy/oxy)propoAy)acetate (DHG Ester)(1.9.2, 
Scheme 2.9). 1,2-Di..Q..hexadecyl-rac-glycerol (DHG) (1.5 g. 2.77 mmo1, 1 equiv.)1 
(2.9.J, Scbe• 2.9) was dissolved in 20 mL oftetrahydrofuran. Sodium hydride (60% 
in mineral oil) (0.44 g, .11.08 mmo~ 4 equiv.) was washed with hexane in a separate 
round bottom flask. Hexane was removed and DHG solution was added to sodium 
hydride at the bottom of the flask. The reaction was allowed to run for 30 min. under 
argon at room temperature. Temperature was lowered to OOC and Ethyl Bromoacetate 
(I .85 g, 11 .08 mmol, 4 equiv.) was added to the reaction mixture. The reaction mixture 
was stirred under argon for 6 hours and monitored by TLC (silica gel 60 F254, EMD 
chemicals, Germany) developed with ethyl acetate/hexane = l /10. Then H~ was added 
and the mixture was washed with diethyl ether. The combined organic layers were dried 
over sodium sulfate, filtered, concentrated in vaccum and purified by silica gel 
chromatography w ith a gradient mobile phase of Ethyl acetate/Hexane (1120 to 1/1 0, vlv). 
(Yield 51%) (MALDI +ve ion mode: 650.6 (M+Nat, 1HNMR (600 MHz, CDCh) (Fig. 
2.12): o 0.83-0.87 (t, 6H, 2 C!b(CH2)w ), 1.18-1.32 (m, 52H, 2 -OCH2CH2(CH., )uCHJ), 
63 
1.53 (m, 4H+ 2 ·OcH:!GHi(CJi2)uCHJ); 3.38-3.68 (11tt 7.1:1~ C~J(~Hi)t4Ct!...,OC!hCHO­








NH2NHz, 180-85 °C 
Ethanol Reflux 6 h 
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II H O-(CH:z)2-o--· --'.&...-NHN.. C-PEG2ooo 
2.9.4 
Scheme 2.9 Synthesis ofDf{G-Hz-PEG conjugate 
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2.1.2 Synthesis ,of2-(2,J-bis(hexadecyloxy)propoxy)eth)·IHydrarinecatbox)'lnte (DHG 
Hydrazide) (2.9.3, $~heme 2.9). Ethyl-2•(2,3~is(hexadecyloxy)propoxy)acetate (2.9.2. 
0.48.g~ () .765 mmol, 1 equiv.)was dissolvedin·ethanol at 50°Cunder argon followed by 
addition ofhydrazine hydrate (2.3 mmok3 equiv.). The temperature was raised to 80-
850G and ~than of. was allowed to reflux for ·6 hours tinder argon. Th~. reaction mixture 
was monitored by TtCdeveloped with .ethanol/ 2%NH40H. The reaction was cooled to 
OOC; the separated precipitate was filtered off and washed with· ethanoL (Yield· 100 %), 
AccuTOF(M +H)+ 613.5 1HNMR(600 MHz, CDCh)(Fig.l.J3): 8 0.84•0.89(t. 6H; 2-
(CH2)tsC!::b), 1.2-1.35 (Ill. 52H, 2 ·OCH2CHz(Clb)nCH3)~ J 56 (m, 4H, 2 -
OCJ-hCfu(CH2)t3CHJ), 3;38.;3.72 (m, 7H,CHl(CH:!)t4CH,QC!::bC!!O.., CH2). 4A (s.2H, 














·· 2.23Synthes;s ofmPEG-2000 Acetaldehyde (2.10~Scheme 2.10) .. Polyehtylene glycol 
2000 monomethyl ether (mP.EG) (2g) was dissolved in 20 mL of anhydrous toluene and 
dried under vaccum. 15 mL of dichJorometbane was added to previously dried mPEG. 
TEMP0(0.035g, 0.224 mmol) was added followed by addition ofBAIB 0 & 3.1 mmol). 
The reactiort was stirred at room temperature overni~ht under argon. ·The mixture was 
then precipitated by addinglSO mL·ofanhydrous diethyl ether. filtered and dried. (Yield 
1 . . . . ·. . . . . . . . . . . . . . . . . . . . . ··.. . . . 56%) HNMR (600 MHz, CDCh)(Fig.l.l4); 6 3.35 (s, 3H), J.50- 3.70 {m. 1 76H), 
4.13 (s. 2H) •. 9.7J (s~lH) 
TEMPO/ 
. . BAIB · · · · · CHO) CH c-o H3C .. ·· O-(CH2CH0)44-·· CH2CH20H . . . • H3CO-{CH2 . :.w- 2 -
· · · · · · Ovemtght 1 
~L H 
2.10 
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. 2.2.4 Synthesis of DHG-Hz-PEG (2.9.4, &he~~te 2.9). Hydrazide activated DHG (O.lg, 
0.172 mmol} was dissolved in ~hloroform followed by addition of mPEG-Aidehyde 
; (0.86g, 0.43 mmol). The reaction mixture was . stirred overnight under argon at room 
; temperature and monitored by TLC developed with CH30H!CH2CI2 1/9 with 2% 
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Fig. 2.1 S TLC showing the formation ofDHG-Hz-PEG lipid 
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•H-seasitivity of DHG-Hz<OPEG 
' 
fhe pH sensitivity of DHG-Hz-PEG was tested by adding 2% acetic acid in the ethanolic 
$Oiution of the reaction mixture. The acidified reaction mixture immediately shows the 
&pot characterstic of DHG hydrazide (Fig. 2.16) suggesting hydrolysis of the DHG-HZ· 
pEG conjugate (Scheme 2.8). 
DHG Hydrazide 
DHG-Hz-PEG 
Fig. 2. t 6 Acidified hydrolysis of the reaction mixture shows the formation of DUG-
hydrazide 
12 
: Sepantioa of DHG-Hz-PEG 
; Separation of the conjugate DHG-Hz-PEG using HPLC did not show any peak with C4. 
. C8 and C 18 Columns. Neithe.r did silica gel column show any conjugate eluting out of 
: the column. Subsequently sepharose-crosslinked 48 gel column ( l em x 23 em* Length x 
Diameter) was used to purify the conjugate using pure water as eluent but did not show 
the conjugate eluting from the column at pH 7.4 . However, at pH JO.S (pH of water 
1 adjusted with 2 N NaOH) the conjugate started eluting out (Fig. %.17). The elution time 
was 30-40 min. 
DHG Hydrazide 
DHG-Hz-PEG 
. . -PEG eluting out of the column 
Fig. 2.17 TLC of the eluent showmg the DHG-Hz 
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'The purification results of the DHG-Hz-PEG cqnjugate at different pH conditions using 
gel chromatography, indicate that the hydrazone-based lipid conjugate is highly unstable 
'at physi()logical pH. 
:Torchilin et al (91) have previously synthesized a series of aliphatic and aromatic 
·.Aldehyde based hydrozone lipid conjugates. Their findings indicate that the half life of 
: the aliphatic conjugates ·were less than 2 min. at pH 55 while the half life of the most 
stable aliphatic conjugate was no more than 2;5 h at pH 7.4. Inclusion of aromatic ring 
next to the . hydrazone linker yielded very high stability where the half lives were more 
than48 hand 72 hat pH 55 and7.4, respectiv~Jy for all the aromatic conjugates. 
Our results show that the hydrazone.:.based lipid conjugates were highly unstable at pH 
7.4 and therefore not suitable for Jiposome preparation and subsequent anticancer studies. 
74 
Chapter 3: Design, Preparation and Characteriati~n ofpH,.~nsidvc Convertible 
Liposomes for Anticancer DrugDclivery · 
. IntrOduction 
~ Advanc~s in liposomal tumor targeting have received consideralYie attention for their 
potential advantages(I02)(l03}including: high drug to carrier ratio, ability to formulate 
lipophilic as well as ~ydrophific drugst targeting to tumor. long circulation halfJifc (I 03 ), 
biocompatibility of the carrier and minimal toxicities of the constituent 'lipids. Th~ 
·advent of •stealth liposomes' have resulted in increased blood circulation. halflife of the 
JipoS<>ines(35)and therefore increased accumulation in the perivascular environment by 
the 'Enbaru:ed Penneation arid Retention Effect'. However the 'PEG coating. of the 
stealth liposome also reduces their interaction with tumor cells (see chapter I, Passive 
targeting) and their penetration in solid rumors( I 11 ). 
To increase the celi.:.JipoS<>nie interaction and intracellular uptake of the drug .a broad 
spectrum of PEG-shedding strategies have been previously introduced ( 104 ). Of note, 
the strategies to shed. the PEG coating from stealth liposomes include the jm:orporation of 
pH-sensitive linkers whiCh can hydrolyze in the low-pH environment (see chapter H). 
However, lipids containing such pH-sen~itive linkers show either poor stability (see 
chapter II~ Separation of DHG-Hz-PEG) at physiological p'H~ or insufficient pH-
7.5 
sensitivity to the mildly acidic pfl in the tumor interstitium (see chapter II, Vinyl ether) 
(77) (79) (80). Fur:thennore, poor stability on shelf is another concern for such 
hydrolyzable.lip()some_s (127). It is thus desirable to develop liposornes that are stable 
both onshel fand in blood circUlation and yet can reniove the PEG coating in response to 
lowered pH. 
This project proposes a stratew to improve the shelf stability andintrac:ellular delivery J>f 
· drug by PEOyJated liposomes. Instead ofusing lipids. w'ith an· acid;.; labile linker we have 
developed imidazole-based lipids that can protonate at low-pH as seen in the tumor 
interstitium. The proposed convertible Jiposomes containingprotonable imidazole lipids 
could convert: from stealth to cationic liposomes in the tumoral interstitium (Fig. J.l). 
The conversion to cationic Jiposome is based on protonation of imidazole lipids and 
chistering of PEG lipids on the 1iposome surface. The newly fonned cationic liposome 
can then have greater interaction with the negatively· charged celt membrane and 
extracellular matrix (123) (see chapter II). Because the liposome converts from stealth 
to cationic Jipo~ome we have giveri them the term •convertible Liposomes'. 
The concept of design (Fig. 3.1) is based on the inherent properiy of the lipids to 





Fig. 3 .I Concept of design of convertible liposomes: protonation and clustering of PEG 
coating on liposome surface in .response to lowered pH. 
The convertible liposomal system essentially comprises of three different types of lipids 
(Fig. 3~3) 1) a negatively charged PEGylated lipid with two Cl6 hydrocarbon chains as 
. . . 
the lipid tail (1 ,2~dipalmitoyl-sn-"glycer<r3-phosphoethanolamine~N-
[methoxy(polyethylene gJycoJ)-2000 (DPPE-PEG, shown by Jetter •p, in Fig. 3~2), 2) an 
imidazole-based, protonable lipid with two CI6 hydrocarbon chains as the lipid tail 
(shown by tetter 'N' in Fig 3.2), and 3) a Cl8 chain lipid DSPC (1,2-distearoy.J-sn-
glycero-3-phosphocholine). that has no net charge. The molecular stimulus that triggers 
the phase separation of the lipids is the acidic pH of the tumoral interstitium. At acidic 
pH, protonable "lipids will protonate and acquire positive charge on the ·surface. The 
protonated· lipids are attracted to negatively charged PEGylated lipids due to the 
electrostatic interaction and vande,r waals force of intera~tion o:wing to the same carbon 
chain length (Fig. 3.3), This leads to the fonnation of PEG cluster on the membrane 
exposing excess posi,tiye charge on tipo$ome surface. Such a fonnulation will allow for 
increased binding with cancer ceUs and higher uptake by the. tumor cells. 
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Fig. 3.3 Three types of lipids (DPPE-PEG, Imidazole lipid and DSPC) comprising the 
convertible liposome, Negatively charged DPPE-PEG and protonable Imidazole lipids 
interac.t ~t low pH 
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Tumor pH 
· The trigger of the proposed convertible liposomal system is the pH of the solid tumor. 
The pH ofthe extracellular interstitium in solid tumor is between 6.0 to 7.0 .(105}(106) 
. ( 1 07) with th~ pH approaching close to .6.0 at the tumor core. The aCidic pH in the tumor 
is due to the heterogeneous network of blood vessels in. solid· tumors which leaves parts 
of the tumor without sufficient oxygen supply (Fig. 3.4). The tumor cells in the hypoxic 
region are forced. to undergo anaerobic glycolysis (lOS) (109) as a major metabolic 
pathway leading to the production of lactic acid and thencethe acidic pH. Additionally, 
findings ofSvastova et aJ suggested the role of carbonic anhydrase lX in the ~reation of 
acidic microenvirorunent in tumor ( 11 0). 




Fig. 3.4 Picture of solid tumor showing heterogeneous and leaky vasculature and hypoxic 
region (adapted with pennission from (128)). 
The convertible Jiposomal system has tunable surface topography (I 24) that starts as a 
stealth liposome and yet converts to a cationic liposome at the pH mimicking the tumor 
environment. The principal behind the formulation development is that the convertible 
liposome will remain masked by the Polyethylene Glycol (PEG) shell during the systemic 
circulation but the PEG shell will progressively de-shield as it encounters low-pH 
environment mimicking solid tumor and thereby exposing excess positive charges on the 
liposome surface acquired by protonation of imidazole lipids. 
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, In this study, we. have synthesized a series of imidazole based pH-titrable lipids with 
increasing pKa values (Fig. 3i5, estimated pKa values· ranging from 5.36 to 6.75) and 
incorporated them into convertible liposomes to·. render liposomes with increasing pH-
sensitivity. The fonnation of lipid domains and the potential of these Hposomes to 
associate with and kill cancer .cells at tumOl'-relevant pH is evaluated in Bl6Fl0 (mouse 
melanoma) and llela (human cervical) cancer cells. 
DHlpKa 553 ± 0.5 
oi_ 
.· H 
o . s-{J 
N 
.~· 
DHMI pKa 6.2 ± 0.5 
DHDMl6.75 ± 0.5 
0 
~i_ JJ 
o . s-{ J 
N 
DPL5.36 ± 0.5 
Fig; 3.5Structure ofpH .. protonable imidaiole lipids 
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. Materials and Methods 
. 3.1 Materials. 1.,2-Di-0-hexadecyl-rac-glycerol (DHG) was .purchased from Sachem. 
·Torrance~ CA, p-Toluenesulfonyl chloride, Pyridine (anhydrous) ·.from fisher scientific~ 
· 1.2-Dipalmitoyl-sn-.glycerol fr.om Chem-Jmpex Intemational, Inc., Wood Dale, IL, 1~2-· 
dioleoyJ-sn-glycetol, 1 ,2-.distearoyl·sn-glycero-l-phosphochoiine (DSPC). 1.2~ 
dipalmitoyl-sn-:-glyceto-3-phospboethanolamine:..N-[methoxy(polyethyJene slycoJ)-2000 
. (OPPE-PEG) from Avanti Polar Lipids, Inc., Alabaster, AL,. 2-Mercaptoimidazole, Tri-
ethyl amine from Sigma Aldrich, 4;.Methyl-1 H-imidazoJe-2-thiol and 4;S-DimethyJ.; 1 H-
imid:.tzole-2-thiol from Oakwood Prod~cts, Inc.~ West Columbia. SC, Doxorubicin 
hydrochloride from Ontario chetni~als, ON. Canada. All organic solvents were purchased 
from Fisher sc·ien.tific, VWR orSigina Aldrich~ 
l .2 Synthesis of E~ter lipid DPI 
J.i~ 1 Synthesis· of sn1--J·((phenylsu/fonyl)oxy}pt'opl!ne-1,2-diJ'I dipalmitote (DPG 
Tosylote) (3.1./, Scheme J.l).. 1,2.'-Dipa·Jmitoyl-sn-gJycerol (DPG) (0~25 g, 0.44 mmol, 1 
equ·iv),~ was dissolved in 20 mL of dichJoromethane, followed by dropwise addition of 
pyridine (1.82 mL, 22 mmol~ 10 equiv). [r'ToltJenesulfonyl chl¢ride(O.J7 g, 0.88 mmol, 
2 equjv) was th.:n added to the above solution. The reaction mixture was stirred under 
argon at room temperarure· for 8 h, and monitored by TLC developed with 
dichloromethane (Scheme 3.1). The reaction mixture was then washed three times with 
saturated sodium carbonate sollJ.tion. The· combined organic layers were dried Qver 
·magnesiUm. sulfate., filtered, concentrated in vac(lu,m and separated by silica gel 
82 
chromatography with dichlorornethane as mobile phase to yieid the product. (Yield 56 
%), DART {M+Ht 551.5 
J.2.2 Syntliesis of (sn)•J-((IH•imidar.ot-2~);1)ilrio)p~;opane•1;1-diJ'I-:-dipalmitate (DP/) 
(J./~2, Scheme J.l)~ 2~MercaptOimidazole (0.1 g. 1.0 mmol, 5 equiv.) was disSolved in 
- DMF and a smaJ.I amouritof Dichloromethane was. added, Triethylamine (0.14 mL, 1.0 
mmol, 5 equiv~) was added to the above solution fQUqwed by (sh)-3-
((phenylsuifonyl)oxy)propane-1,2~iyldipalrnitate (0.15 g, 0.2 mmol, I equiv) and the 
reaction was allowed to run fo~ 48 h at ss·c under argon. The solvent was evaporated 
and reaction mixture was re-dissolved in ethyl acetate and washed thrice with saturated 
sodium bicarbonate solution. The combined organic layers were dried oyer s.odiurn 
carbonate, filtered, concentrated in vacuum and separate<! by silica gel chromatography 
with Ethyl acetate I Hexane = 3n as mobile phase to yield the product (Yield 9-%), 
DART(M+Ht 65l.5 (Fig. 3.6), 1H-NMR (600 MHz, CDCh) (Fig. 3.7): o 0.87 (t, 6H. 2 
CH3(CJ·b)15-), o 1.15-1.35 (m, 52H, 2 -OOCCHiCI-h(Cfu)hCHJ), o 158 (t, 4H, 2 -
OOCCH2CH7(CH2) 13CH3), o 23 (t. 4H, 2 -OOCCJ:hCfh(CH2)t3CI-h), o 3.38, 3.66 (q, 
2H, -l::hCSCNH-), o 42, 4.4 (q~ 2H, CH3(CH2)t4COOC.l:b-), o 7.08 (d, lH, 
H2CS0==NHC='CH-NH-)~.o 8~04 (d, 1H9 H2CSC=NHC=CH~NH-) 
0 
, . . . II 
CH3(CF.l7l1 .. :-C..,.,.-(? . 
· ·C}Ij(CH2)t4;-C-Q · 
·. .· .. II 
() 
() 
.. . u 
CH3(CH2)14-C-'·o . 
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. 3.3 Synthesis ofEther lipids DHI; DHMI and DHDMI 
, J.J.l Syntllesis of 1,2"-Df ... O·hexadec)'l-rac-g/ycet)•/ tosJ'Iate (DHG ToSJ•/au) (3.2.1, 
Sclteme 3•2). 1,2-Di;.Q. .. hexadecyl~rac;.g)yc~rol (DHG)(2.43 g, 4,5 mmol, 1 equiv}, was 
· dissolved itt20 rnL ofdichJoromethane~ followed by dropwise addition ofp)'ridine{l8;6 
mL, 225 inmol, 50 equiv). pToluenesulfony1 chloride (1.71 g, 9.0 mmol, 2 equrv) was 
then added to the above solution (Scheme·3.l). The reaction mixture was stirred under 
argQn at rorim , temperature for 8 h, and monitoted by TLC (silica gel 60 F254, EMD· 
chemiCals, Gennany) developed with dich1oromethane. The reaction mixture was then 
washed three times with saturated sodium carbonate solution. The ~ombined organic 
I~yers wer.e dried over magnesium sulfate~ filtered, concentrated in vacuum and separated 
by silica gel chromatography with dichlotornethane as mobile phase to. yield the product. 
(Yield 65 %);, DART (M+H)+ 695.5~ 1H·NMR(600 MHz, CDCh.-6 ppm): 0.87(t, 6H. i 
CI:b(CH2)w), l..i8-L3l (m, 52H, 2 -OCH2CHi(CH~)13CH]), 1.4"6 (m, 4H, 2 -
OCH2Cfu(CHz)t3CH3), 2.44 (s, JH, -(C6H4)Cfu), 331-3.61 {m, .5H, 
CH3(CHz)14CfuOC!:bCHQ.;), o 4.14 (m, 2H, ..C!bSOt~), S.7.3l(d, 2H, aromatic protons 
or tho- to ~S02~ ), and fJ7 .78 (d, 2H, aromatic protons ortho-. to·CH3-) 
3.3.2 Synthesis of (sii)~2-((2,J-bis(hexadecy/oXJ')prop}'l)thio)~J H-iinldazole (DHI) 
(3.2.2, Scheme 3.2)~ 2- Mercaptobnidazole (0.66 g,. 6.61 mmo~ 5 equiv.)·was dissolved 
in DMF and ;:t small amount of Dichloromethane;was added. Triethylamine (0.92 mL, 
(;.61 mmol, S equiv.) was added to the. above solution followed by 1 ,2;;.Di•O-hexadecyl-
rac~glyceryJ tosylate (3;2.1) (0~92 g, 1.32 mmol, lequiv)and the reaction was aUowed to 
run for 48 b at 5'5''C under argon (Scheme 3.2). The solvent was evapotated and reaction 
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mixtUre was re-dis~olved in ~tbyta<;etate and washed with saturated sodium bicarbonate 
solution (3x). Th(! coinbirie(f organic layers were dried over sodium carbonate, filtered. 
concentrated in vacuum and seperated· by. siiic~ . gel chromatography with Ethyl .acetate / 
Uex:llJ)e = 3(1 as :ti10bile phase. (Yield 26. %), QART(M+Ht 623.5 (Fig. 3-.8). 1H-NMR 
(600.l\1Hz, COCb) (Fig •. 3~9): o Q;87 (t, 6f{,.2 C!.!J(CH2),~~), o 1J9-Ll2 (m, S2H.2 """' 
OCHiCH2{Clli)13CH3)~ 6 1.55 (m, 4H, 2 "-OCH2CH.;(CH2)13Cl-h, 5 3;22~ 3.65 (d.t:f2H, • 
H.,CQCJh(CH2}1.tCH3), ~;: 3..38.., 3~6 (d,d 2H, - ,lliCSCN.f:l~)~ o ~.44, lSS (m, 4H. 2 -
H2COCfu(CB2)t4CH)), ·~ 3~73 (m, 1 H, CH3(CH2)rsOCH~). o 7;02 (d, lH. 
. HtCSC=NHC==CH-NI-i-), o 7.21 (d~ 11:1. H2CSC=NHC=CH.;NH~) • 
CHz(ClJ~I5:=J 
CH2(Cif2lts .~ L + 
OH 
0 
O=a-f"\ .. · . · .··CH 





CH2(CH2)ts-o 0 CHz{CH2)u·o=t· ·.  . . 
. II o-· .· ·.2 "·.:t 
·. -0- . . Cfi3 J.s. 
H · .. 
N ·• R1 
Hs-(X 





::::::: ==t_·.. .·H . R Nx · ·· .. ·· s-( 1 . . 
N · ··R 
"2 
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DHI R1 = H, R.2 = H (3~.2.2) 
OHMI R1 = Cll3, R2 = 1-1 (3.2.3) 
DHDMI R1 = CH3~ R2 = CHi (3~2.4) 
Scheme 3.2Synthes1s ofDHI, DHMI and DHDMI 
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3.3.1 Synthesis of sn·2-((i,J-bis(hexadecyloXy)propyl)tllio)w5.;.meth)'I~JBw imidazole 
(DHMI) (3.2.3, Scheme J.2). 4wMethyl-1H-imidazole-2~thiol (0.75 g, 6.61 mmol, 5 
equiv.) was dissolved in DMF and a small amount of Dichloromethane was added, 
Triethylamine (0.92 mL, 6.61 mmol, 5 equiv.) was added to the above· solution followed 
by 1,2-Di-0-hexadecyl .. tac-glyceryl tosylate (3.2.1) (0.92 g, 1.32 mmol~ 1 equiv) was 
then added to this solution _and. reaction was allowed to run for 48 h at· 5 5"C under argon 
(Scheme 3.2). The washing and purification was the same as mentioned in 3.3.2. (Yield 
22 %), DART(M+Ht 6375(Fig.J .. l0). 1H·NMR (600 MHz, CDCh)(Fig. 3.1 1): o 0.87 
(t. 6H, 2 C.lli(CH2),5·)~ c5l~l9-1.34 (m~52H, 2 -QCihCI:h{CH,)uCHJ), o 1.53 (m,4H, 2 
-OCH2Clli(CH2)t3CH3), 52.31 (s; 3H, -HzCSC=NHC=CH-C!h), o 324, 3.66 (d,d, 2H~ -
fuCOCH2(CH2) 14CH3), o 3.4, 3,6 (d,d 2H~ "' _lliCSCNH~). o 3.44, 3.55 (m, 4H, 2 • 
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3.3.4. Synthesis . of sn~2-((1,J-bis(hexadec)"'oxy)prop)'l)lhio)-4;5-iit~tii)'I-JH~i,idal.()/e 
(DHDMI) (3.2.t/, Scheme 1.2). 4.:Methyl-lH-ilnidazofe-2~thiol (0.84 g~ 6 . 6 J mmol, ~· 
equiv .) was dissolved in DMF and a small amount of Dichloromethane w~s added. 
Triethylamine (0;92 mL, 6.61 mmoJ, S equiv.) was added to the ~bov¢ S0lution.foJiowed 
by i;2-bi.:O-hexadecyi~rac~gtyceryl tosylate (3.2 .. 1) (0,92 g, 1.32 mmol; I equiv) and 
reaction was allowed to run for 48 hrs at ss·c under argon (Scherile 3~2). The washing 
and purification was similar as mentioned in. 3.3;2 {Yield22 %), DA.RT (M+Ht 651.5 
(Fig. 3.12), 1H-NMR:(600 MHz, CDCIJ) (Fig. 3~13): .o 0.87 (t, 611, . .2 Clb(CHz)l5~). o 
L 19-,1.34 (m, 52H, 2 -OC~2CH2(Clli)tJCH3)~ o 1.53 (m, 4H, 2 -OCH2C.th(CHz)uCH3), 
52.11 (s, 3H, -H2CSC=NHC=Cft..,C.lli) •. o 2.17 {s, 3H,. -H2CSC=NCC.lli); o 3 .14; 3.65 
(d,d 2H, ~!hCOCH2(CH2)a4CH3), o .3.29, 3.59 (d~d 2H~ - !bCSCNH~) •. o 3A2,. 355~ (m, 

































3.4 ,Calculation of p:Ka. The pka of the lipids (DHI~ · OHMJ, DHDMI and .DPI) was 
calculated using ACD/pKa DB softWare (Advanced Chemistry Developmet, Inc., 
! Ontario, Canada)(l26). 
3.5 Preparation otl..iposomes. Liposomes were prepared by lipid film hydration and 
extrusion (98). Chloroform solutions of appropriate lipids (Table 3.1) were mixed in a 
25 · mL round bottom flask~ Chloroform· was evaporated in a Buchi rotavapor and funher 
dried in vaccum oven for 3 hours at room temperature to. remove traces of the solven~. 
The lipid film was then hydrated with HEPES buffer {pH 7A,. 5 mM HEPES) with or 
without 140 mM NaCI using intennittent agitation to obtain a suspension of · 7.5 mM 
total lipids. For pH dependent· change of Zeta potential measurements •. interaCtion 
between convertible and model Jiposomes and nsc experiments liposomes were 
prepared in () mM NaCJ whiJe for the cytotoxicity and doxorubiein uptake experiments, 
140 mM. NaCl was used to prepare liposomes. The Hposorne suspension was freeze· 
thawed (alternate immersion in dry ice/acetone and water bath at 40 °C) eleven times and 
extruded sequentiaUy through 40Q rim and 200 nm poJycarbonate membranes 
(Nucleopore Corp., Pleasanton, CA) using .a Mini.extruder (Avanti Polar Lipids fnc:. 
Alabaster, AL) at7o• :C to yield the liposome preparation. The particle diameter and ~· 
potential of the preparations were measured by photon correlation s~ctroscopy 
(Zetasizer ZS90, Malvern. Instrum-ents Ltd., UK). 
The average liposome sizes for all the formulations studied ranged from 200-270 nm 
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3.6 Composition of*Convertible.. Control·and 1\fodd lipc>s()me$ 






om DHMI DHDMI DSPC DPPE-PEG 
I 25 70 5 
II 25 70 5 
HI 25 70 5 
IV 95 5 
*The ester basecl ifJiidazole lipid (DPJ) was not used for liposott1e prepranion and 
subse.quent experiments because oflow yield and expensive pr~cursot lipids. . 
Model liposomes (118) (ll9), that ·mimic the lipid composition of biomembranes were 
prepared with the lipid <:Qmposition 50 mol .% POPC, 20 mol % POPE, 5 mol %POPS, 
lO mol % L-a-PI and 15 mol %cholesterol 
3.7 pH dependent change of Zeta potential. The pH of an aliquot (lmL) of a liposome-
suspension· (see section 3.5) was adjusted \\lith acetic acid ( 5 ·. mM, final pH con finned. by 
pH meter) immediately before taking zeta potential . measurements. The zeta potentials 
were m.easured at 37 °C by electrophoresis mobility under applied voltage using Zetasizer 
ZS 90 (Malvern Instrument, Malvern, UK). 
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3~8 lnt~racdop betw~en ~oavertible and model liposomes. Liposome suspensions of 
pH.;serisitive liposomes •~ II~ Uland IV (see section 3.5) were ·mixed with equa1 vol\,lme 
of model liposome (see section. 3.S} and pH was adjusted. with acetic acid · (5 mM, final 
pH confinned by pH meter). The liposome mixture was incubated for. one hour at 37 °C 
and average sizes were measured at 370C by dynamic light scattering \ISing Zetasizer ZS 
.90 (Malvern Jnstr\lment, Malvern, UK). 
3.9 Differential Scanning Caiorimetry of liposome formulations I . and IV. A VP-
DSC Instrument (MicroCal, LLC, Northampton, MA) Was· used for the differential 
scanning calorimetry (DSC) studies. DSC scans were performed. oil vesicle Suspensions 
of0:5 mL sample volume containins 2.5 mMtotal lipid at pH values 7A and 6;0. The 
thermograms of vesicle ~uspensions. were acquired ftom35°Cto 70°C at a scan rate of 5° 
Clh. The excess heat capacity curves of samples were normalized by subtraction of the 
thennograms-.of the buffer acquired simultaneously under identical conditions. 
J.lO Loadingofdoxorubi~in (D()X) in Jiposomes 
3.10./ Doxorubicin loading by ammonium sulfate gradient. Earlier in the study, the 
remote loading of doxorubicin into liposomes were .driven by a transmembrane 
ammonilim sulfate gradient according to reference .(99) (100) with minor modification. 
Briefly, chloroform solutions of appropriate lipids (Table 3.1) were mixed in a round 
bottom flask. Chloroform wa.s evaporated in a Buchi rotavapor and further dried in 
vaccum oven for 3 ·· hours ·at room temperature: to remove traces of the solvent. Each lipid 
film was hydrated with 250 mM ammonium sulfate solution in water and agitated 
intennittently to fonn·a liposomesuspension. ThepHofthe ammonium sulfate solution 
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was adjusted to 7.0 with ammonium hydroxide solution. The resultant liJ)9some 
suspension was freeze/thawed (dry ice/acetone, water bath at 40 °C) eleven times and 
extruded sequentially through a 400 run arid a 200 run poJycarbonate membrane 
(Nudeo.pore Corp., Pleasanton. ·CA) using a Mini~extruder (Avanti Polar Lipids Inc., 
Alabaster; AL) at 70 °C to yield the Iiposome preparation. To establish the: 
transmembran~ ammonium sulfate gradient, the extruded Uposomes were separated from 
unencapsulated ammonium sulfate by a Sephadex G-25 column (Sigma, St. Louis, MO) 
equilibrated with isotonic HEPES buffered saline (5 mM HEPES, 140 mM NaCl~ pH 
7.4). One volume of 0. 75 mg/mL DOX in the same isotonic HEPES buffered saline was 
added into 2 volumes of liposome suspension (lipid concentration =· 7.5 mM) and 
incubated for 1.5 h at 70 °C. The liposome preparations were then passed through 
Sephadex G.-200 column eluted with isotonic HEPES buffered saline to separate the 
liposomal-DOX from unencapsulated DOX. 
3.10.2 Doxorul!icin loading by manganese sulfate gradienL Later in this study, the 
"loading of doxorubicin was driven by a transmembrane manganese sulfate gradient ( t 01) 
with minor modification. Lipids film was prepared as mentioned eariier (see section 
3.5). Each lipid film was hydrated with 300 mM Manganese sulfate solution prepared in 
HEPES buffer (pH 7.4t 5 mM HEPES, 140 mMNaCI) arid agitated intermittently to get 
the Iip·osomal suspension. The resultant liposome su~pension was freeze/thawed (dry 
ice/acetone, water bath at 40 °C) eleven· times and extruded sequentially through a 400 
nm and a 200 run polycarbonate membrane (NucJeopore Corp., Pleasanton, CA) using a 
Mini·extruder (Avanti Polar Lipids Inc., Alabaster, AL) at 70° C to yield t1te Jiposome 
preparation. To establish the transmembrane manganese sulfate gradient, · the extruded 
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lip<)somes Were separated fr<>m unencapsulated ammonium sulfate by a Sephadex (j .. 2s 
column (Sigma. St. Louis~ MO) equilibrated with isotonic HEPES- buffered saline (S mM 
HEPES, 140 mM l\laGI~ pH 7.4). l volume of 0~75 rnglmL OOX in the .same isotonic. 
HEPES buffered saline was added into 2 volumes of liposome susl?ension (lipid 
concentration = 7.5 mM) and incubated for 1.5 h at 70°C. The liposome preparations 
were then passed through· Sephadex G:-2()0 column eluted witl:l isotonic HEPES buffered 
saline to separate the :liposomai-OOX from unencapsulated OOX, 
3.~11 [)cterinination of DOX concentration .and encapsulatio,r efficiency. An aliquot 
of a D()X'-Joaded liposome formulation was lyzed with 90% ist>propanol containing 
0.075 M HCI (125) foiJowed by quantification of the released DOXby Spectroflurometer 
(Shimadzu, rf5301 pc. Ex.= 484 nm, Em.= 587 nm). The OOX in the corresponding 
liposome formulation before purification was quantified in parallel. The Encapsulation 
Efficiency(EE)ofthe liposome formulation was then calculated usingtheformula: 
. . 
EE= . DOX in purifed lipo.mme fi)rmulatian . x JOOolo 
DOX inliposOliJe formtllation before purification 
DOXencapsulation by MnSO-t yielded an EE40-45% for all the liposome fonnulations 
while the encapsulation by (NH.)2S04 yielded an EE ~·12 % 
3.12 Dc)xorubi~in retention studies .. Retention of OOX in Jiposomal fonnulation J was 
determined by equiHbrium microdiaJysis using rapid equilibrium dialysis device (Thenno 
Scientific, inserts with membrane, MWCO = 800() Da) according to manufacturer's 
recommendations. The pH ofliposome fonnulatlon of OOX (see section 3.10.2) was 
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adjusted with MES buffer (pH 5.937 50mM~ 145niM NaCI). Preci~ly~ 40, 100 al1d 500 
f.!L of theMES buffer was added to lmL ofliposome suspension roadjust the pH to 6.97. 
6.5 and 6.05 respectively. 100 JJL of 1iposome SIJSpension was. add-ed to the sample 
chamber while 300 fJ.L of buffer was added to tile bl).fer chamber. The percent DOX 
retained in liposomes at different time points was calculated using the following 
equation. 
% DOXretained = 100 x{l- (Vb+vs)(Cb)) 
CdVd ·. 
Where, Vb = Volume of buffer chamber, Vs = Volume of sample ~harnb(r, Cb = 
concentration of DOX in. buffer chamber, Cd = initial Jiposomaf DOX concentration 
added to sample.chamber,Vd = initial volu~eofsample .chamber 
3.13 Cell (ultore (onditions. The 816-FiO (murin~ melanoma) cells and Hela (human 
cervical cancer) cells were purchased from American Type Cuiture Collection 
(Rockville~ MD). Bl6 .. FJ O cells were maintained in DMEM media supplemented with 
lO% feta1 bovine serum, J% Glutamine and I% peniciUin-streptornycin. Hela cells were 
maintained in EMEM media supplemented with IO%fetal bovine serum, 1% Glutamine 
and f% penicillin:-streptomycln. Cells we~ cultured with complete medium at 37oc in a 
humidified atmosphere of S% CO:! in air. ·Cell concentrations wete determined with a 
cell" coulter counter. 
3.14 MTS cytotoxicity assay on B16FlQ alid Hela cells. f3J6.;FJO cells f- 20,000 
cells/well) and Hela cells (:- 80~000 cells/well) we~ seeded on 96·\VelJ plates and grown 
overnight in complete- medium. The cells ·were then . washed with ·pas· and treated with 
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tOO !!L o(either complete or serum free media containing free DOX. Liposornal.DOX at 
a dosage .of 0.1 ~ 1 .0. 10.0 pg OOX per mL and empty liposome fonnulation 1. 
The pH of the media (10 mL) was adjti$ted with glacial acetic acid (Table J.2)and final 
pH was conflimed with pH meter. 
Table3.2 Adjustment of pH of the media wi.th glacial acetic·acid 
Media Glaciat ·AceticAcjd btL) 
(lO mL) pf{7~0 pH 6.5 pH 6.0 
OMEM 
(Serum F~ee) 
65 13 20 
DMEM 7 17 20 
(Cornol¢te Media) 
EMEM 05 2 s 
(Serum Free) 
EMEM 05 3 6 
(Complete Media) 
Each test was perfonned in quadruplet Cells were incubated for 3 h and J 2 h at37oc 
and 5% CO:!. After incubation for 3 and 12 hours respective·ly, the medium wAS 
removed, and the cells- were washed three times with 100 pL PBS buffer and 
supplemented with 100 ,.uweil of the cornpJete medium and 20 J.!UW.¢11. of ~tTS'•based 
CelJTiter 96® AQi.le0\8 One S~lution Cell Proliferation Assay Reagent (Ptom:ega Corp., 
WI, USA) and incubated at 37°C for2 h. The absorbance at 57(1 run w~s. measured using 






The cells thatare not treated by any formulations were grown at pH's 7.4. 1.0. 6.5 and 
6.0 and their viabilities were detennined by MTS assay to rule out significant cytotoxicity 
caused by the change of pH in the media. 
' 3:JS Quantitation ()(~ellul~r uptake ofdoxorubicin with now cytomdry. Bl6~FJO 
cells (- 6'00,000 cells/well) wete seeded on 6.-well piates and grown overnight in 
co~plete medium.. The cells were tlten wa5hed with -PBS and treated with 2 mL of serum 
free media containing either free pox or DOX loaded liposome formulation II at a 
dOsage of 10 flg DOX per mL. The pH of the media was adjusted with glacial acetic acid 
(Table 3.2). Cells were incubated for 4h at .37°C and 5% COt. After -incubation cells 
were detached with detach in (Oenlantis; San Diego; CA), centrifuged and res\lspended in 
PBS before taking measureme.nt in .FL2-H channel in F ACScan (Becton Dickinson, San 
Jose, CA. US.'\). 
Results and Discussion 
3~16 Design ofimada:zole-basedlipids. We· have choserlimidazole head group in our 
lipid design due it's unique properties. The Nl position ofimidazo1e moiety is basic and 
.protonates at mildly acidic conditi()ns (130). AdditionaJiy, addition · of methyl group at 
the C4 and C5 position of the imidazole moic~ty gives the .. flexibility to tune the pKa of the 
molecule to a higher value (Table 3.3). When incorporated into liposomes. the 
protonation of imidazole at low pH pn>vides positive c-harges . to these · lipids which 
interacts with. neg~tively charged PEGylated lipid (DPPE-.PEG). To further aid this 
interaction, we ba.ve chosenG16 chains as lipid tails for the imidazole lipid which renders 
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additioru!J force of attraction (Vander Waals) with the Cl6 cha·in DPPE-PEG owing to 
same chain length. 
3.17·Synthesis of imidazole-based, pH-t~tratable, lipids. The synthesis of both ·ester· 
and ether based lipids were earned out to yield a ~fies of pH titrable lipids. The 
synthesis was based on ·firSt the tosyl activation of the commercially available lipid 
(DHG J or (DPCJ) with para tolpeJ1e sulfonyl chloride and· then substitution of the tosyl 
group with the imidazole moiety using mercaptoimid~zole compounds (l J 2) (l J 3). 
Tosylate is a good leaving group and therefore was exploited for the conjugation oflipid 
with the imidazole compounds .. the high temperature conditions were maintained and 
DMF was added to the reaction mixture because of the- limited solubility of 
mercaptoimidazole in dichloromethane. The-reaction time was optimized for best yield 
and at the same time fewer side products. 
3.18 Lipid pKa calculation. The pKa ofthe lipjds{DHI. DHMDI, DHDMI and DPI) 
were determined by ACD/pKa software. Catcuiadon was used rather than the 
experimental methods for pKa detennination as these lipids assemble in aqueous media 
and therefore it,s bard·to. trace each molecule. Additionally pKa .of a lipid molecule is 
sensitive to its lipoSQmal environment. W,e calculated this. but later did the:zetapotential 
measurements of lip(>sornes composed of these lipids was measured at different pH 
conditions to ,monitor the protonation process which is more rilevantto the function of 
these lipids. The im idazole•based lipids showed estimated pKa ranging from 5-36 to 6. 7 5 
(Table 3.3). 
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Table 3.3 Calculated pKa of Imidazole based Lipids. 
Lipid pKa 
nm 5.53 ±.0.5 
DHMI 6.2 ±0.5 
DHDMI 6.75" .± 0.5 
DPI 5.36 ± 0.5 
3~19 Zeta potential measurements. The ability of the imidazole lipids .to protonate at 
. mild .acidic condtions wneri incorporated in liposomes has been previously demonstrated 
( J 16)~ moreover their efficiency as carriers for gene transfer has also ·been ~xamined at 
acidic pH (114)(117). 
The convertible liposomes (I. II, Ul). prepared and tested herein, show increase in their 
zeta potential with increasing pKa of the corresponding imidazole lipids. The liposome 
formulation l:shows an increase in average zeta potential value from . .;5.43 mVatpH 7.4 
to 2.72 mVatpH 6.0 while formulation n shows ;zeta potential increase from ·2.5 mV to 
5.04 mV (Fig• 3~14 (a), (b)). The liposome fonnuJationlll starts at ... 0.93 rnV and reaches 
12.99 mV value at ;pH ~.0. The zeta potential change of the control liposomeJV did not 
show signi'tlcant <:hange in the zeta potential values from pH7.4 to pH 6.0. The increase 
in t¢ta potential values ofthe pH tunable liposomes is indicative of the protonation ofthe. 
imidazole lipids, moreover the increase in zeta potential values is consistent with the fact · 




·final zeta potential values, suggesting the protonation. of more ·number of the imidazole 
lipids with increasing pKa of the lipids. 
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Fig. J.l4(b) Change of zeta potential values Qf liposotne fonnulations (I-IV) with 
percent (%) Ionization of imidazole lipid ·incorporated in eonvertible liposomes. 
•Percent Ionization was calculated by Henderson-Hasselbal~h equation using 
estimated average pKa values of imidazole lipids. 
3.20 Phase separation of Jip(,lsome into lipid domains (DSC characterization). The 
liposomes prepared with saturated lipids ofcarbon chain lengths diffe,ring by only two 
carbon· atoms or Jess show ideal mixing of lipids (120) (121). The OSC thermogram ·of 
lipoSome I (Fig. 3.15) show one broad melting ~ak at pH 7.4 between 56 °C to 65 °C 
indicating hom()genous mixing of the Ct6 and Cl8 chain lipids. At pH 6;() the 
fonnulatlon I shows the emergence of a second broad peak at 52° C suggesting the 
fonnation of the domain rich in DSPCJipids (Tm = 55 °C) doped with the :C 16 chain 
imidazole- lipids. The formation of 1he. DSPC domain- on the Jiposome is due to the 
interaction of newly protonated imidazle Jipids and negatively charged PEGylated lipids 
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Fig~ 3.15 DSC t.flerinogn!ni ofcontroLliposome IV and convertible Jiposome 
fonnulation I 
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The DSC thermogram of the control liposome IV (Fig. 3.l5) show one melting ·peak 
suggesting the homogenous mixing. of lipids at both pH 7.4 a~d 6;0 and therefore a one 
• phase system~ 
~-2l Interaction of convertible liposomes with model liposomes mimic){ing 
cell membrane. To evaluate whether the in~rease in the ·zeta potential values ii'J fact 
translates into interaction with negatively charge cell membrane~ we prepared model 
liposorne ( 118)' (J 19) cai"tying t 5 mol % of. negatjveJy charged lipids to mimic the 
charge of the cell membrane (85) (8S). The convertible !iposom¢s. were mixed with equal 
volume of equimolar ;model liposomes and their sizes were measured at .different pH 
conditions. 
Tbe increase in the average size of the model Hposome upon mbdng \\ ith the rlt 
convertible- Jiposomes is consistent with the increase in th~ pKa ,-a lues ofthc inti,.U.ttlk 
lipids and the corresponding increase in zeta potential of the res~('tivc: liposomcs (f'ia:. 
3.16). Liposome formulation III shows approx. three tirn~s increase in a-\cragc sitt' 
values at pH 6.0 (:::: 2770 nm) compared to average sizes at pU 7.4. Simit;nb 
fonnulations I and ll show increase in average sizes 3.5- to 4- times >the \:alucs at plf7A . 
The average sizes ofthe Jiposomes ofthe control liposomc on the mhc:r hand ~ht)\\cd no 
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· 3.22 Doxotubiein loading in liposomes~ Doxorubicin has been conventionally Ioad'-'"d 
in liperomes using an ammonium sulfate gradient wherein the concentration of 
ammonium sulfate is higher in the Jiposome than· the extraliposomal medium. The pH 
. inside .the liposome is maintained at 4M5 pH .units while the extraliposrnal pH is at pH 7A 
The re_mote ·toading of DOX occurs when the unprotonat~ DOX molecule diffuses from 
the ~xtraliposo~alspace ·and gets charged atthe low pH environment inside the liposomc 
and fot1llS a sulfate salt from the. sulfate of the ammonrum sulfate ~olution {fig. J.J7). 
The DOX -sulfate salt is then precipitated in the low pf I environment. The limitation with 
this approach is. the t¢q~irement to form the liposomcs at low pH environments which is 
a cha1Jengingtask for pH sensitive liposomes. 
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' For our study, we· firstattempied a modificati<>n in· this. pt:ocedure where w¢ adjusted· tl}e 
(NI-I4)2S04 solution to·pH7.0 instead·ofpH4-5 ~nd thenpr£>ceededwith lipid hydration, 
extrusion, purification and remote loading of DQX. However, StiCh IllOdifkation resulted 
in poor [)OX encapsulation(:::: 12 %) and poor DOX reteniion where only 40% ofthe 
DO X remained inside the Iiposome after 50 h ofincubation at pH 7 ;4 at37 °C (Fig .. 3.18) 
-




0 70 J 
·- I .... c .. 60 • cu . ~ .... CU. 50 1.2:·.· c: 
40 
[ . 
·-· -~ u 1. 
·-· I .a 30 2 ' 0 20 I )( -t 0 !. 
0 10 j 
0 l ·-r----,..- --,-~ .. - -.-- - ·-,---c--·--,. 
0 10 20 30 40 so 60 
Time(h) 
Fig. 3:.18 OOX retention in convertible liposome fonntllation I at pH 7A prepared by 
a:rl1ino11iurn .sulfate gradient.method 
J To circumveri1 this problem we prepar~ the IipoS()m~ itl mang:nese sulfate solution 
I 
1 mainta:inedatpH 7.4 (101). The manganese is known to complex ~wiih OOX molecules-




with this method was at' around 64 % at pH 7.4 and . 56 % at pH 6.0 after 48 h of 
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:Fig. 3J9 DOX retention in liposorrie formulation I prepared by mangane~e sulfate 
method 
3~23 Cytotoxicity of convertible Jiposumal·formulations ofDOX •. Bl6FIQ andHela 
cells were treated with all the iiposomatfonnulations (I~IV)'and free. DOX. The free 
DOX was studied as positi~e .control white .Ilposome IV was taken as a negative control .. 
AHthe fonnulations show·dose dependent c)itotoxitityin both ~ell l~es. The pHtunable 
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liposomes show increased cytotoxicity as the pH is loweredfrom·7A to 6.0 at 10 Jlg/mL 
DOX concentration both in complete media and serum· free media. In B 16fl 0 cells, the 
average tell viability values for formulations l, nand III were:::: 71 %, 75% and 50% 
respectively at pH 7.4 while the averages values were :::: 59-%, 57 % and 41 %at pH 6.0 
in serum free media at 10 Jlg/mLDOX.concentration after 3 hrs of incubation (Fig. 3.;2.0). 
After 12 hr ofincubation the average cell viability values were:::: 57 o/o, 54 and 42% at 
pH 7.4 and:::: 46 %, 43 % and 31 % at pH 6.0 respectively for .liposomes I, U, and Ill 
(Fig. 3.21, 3•28). The control liposome IV did not show any significant difference 
between the cell viabilities at pH 7.4 and 6.0 after 3 and 12 hrs of incubation (Fig. 3.20, 
3.21 ). Free DOX was the positive control and showed highest toxicities with cell 
viability at :::: 25 % after 12 hours o( incubation at both pH values (Fig. 3~21, 3~28). The 
c.Ytotoxities we~ diminished for all fonnulations in complete media. After .3 hrs of 
incubation although there was a clear trend in the decreasing cell viabilities as the pH 
decreased from 7.4 to 6.0, the values were not significantly different (Fig. 3.22). 
However after 12 hours of incubation the cytotoxicity values for fonnulations I, 11, and 
III became significantly different with liposome Ill showing highest cytotoxicity .at :::: 
61% and:::: 52% cell viability at pH 7.4 arid 6.0 repectively (Fig.-3.23). 
For He Ia cells, the cell viabilities w¢re :::: 67 %, 65 % and 53 % at pH 7.4 and ::::55%, 53 
%and 43% at pH6.0 respectively for fonrtu1atioris I, II and lll after 3 hrs of incubation 
in serum free media (Fig. 3~24). After 12 hrs of incubation with the convertible liposome 
formulations I, II and III the cell· viability values were :::: 63 %, 58 % and 38 % at pH 7.4 
and :::: 50 %, 46 % and 28 % at pH 6.0 (Fig. 3.25, 3.19). Free DOX showed highest 
toxidty with :::: 22 % at both pH 7.4 and 6.0 (Fig. 3.25, 3.29). The observations for 
Jl5 
cytotoxicities in complete .media were similar as observed . in B16Ft0 cells where cell 
viabilities did not show any significant difference at pH 7.4 and 6.0 for fonnutations 1? H 
an£! m (Fig • . 3.26). However cell viability difference at pH 7A and 6.0 did become 
significant after 12 hours of incubation (Fig. 3~27) with. Jiposome III . showing highest 
cytotoxicity at59 % and 51 %at pH 7A and 6.0 respectively. 
For both the cell lines the increase. in toxicity was greater after 12 hours of in~ubation 
compared to the 3 hr of incubation which indicates .the high uptake ofdrug by the ceHs at 
longer times. Additionally, the difference-in the cytotoxicity (>f the c()ntr()l lip()some JV 
remained insignificant at pH 7.4 and 6.0 at all DbX concentrations suggesting .its lack of 
interaction with the negatively charged cell surface~ 
Furthennoret at both iilcubatic:m times~ the cytotoxicity was greater for fonnulation III 
which is consisteJ}t with the lip050me binding assay with model liposome, suggesting 
more interaction of liposome with higher percentage of positive charges at low pH with 
the negatively .charged cell surface and hence higher uptake and greater toxicity~ 
Also, the cytotoxicity ()felripty liposome I remained insignificant for all the experiments 
indicating inherent insignificant cytotoxiciiy of the, imidazole lipids. 
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Fig. 3.20 Cytotoxicity of free OOX, liposome formulations of DOX and empty liposome 
(formulation I. without DOX) against B16-FI O murine melanoma cells in serum-free 
medjum after three hours of incubation. Mean and SD of cell viability {%) are presented 
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Fig. 3.21 Cytotoxicity of free OOX, Jiposome formulations ofDOX and empty Iiposome 
(formulation I without OOX) against BI6~Fl0 murine melanoma cells in serum·free 
medium after twelve hours of incubation. Mean and SD of cell viability(%) are presented 
(n = 4) (* p < 0.05, student t· test) 
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Figure 3.22 Cytotoxicity of free OOX, liposome fonnulations of DOX and empty 
Jiposome (fonnulation I without OOX) against B 16-FJO murine melanoma cells in 
complete medium after three hours of incubation. Mean and SD of cell viability(%) are 
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Fig. 3.23 Cytotoxicity of free DOX, liposome fonnulations ofOOX and empty liposome 
(tonnulation I without OOX) against 816-FlO murine melanoma c.ells in complete 
mediwn after twelve hours of incubation. Mean and SD of cell viability (%) are presented 
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Fig. 3.24 Cytotoxicity of free OOX, liposome fonnulations of OOX and empty liposome 
(fonnulation I without DOX) against Hela cells in serum-free medium after three hours 














Untreated 0.1 tJgfml 10 J.lglml Emptylipo. 
COX Concentration 
Fig. 3.25 Cytotoxicity of free DOX, liposome fonnulations of DOX and empty liposome 
(foimulation I without OOX) against HeJa c-ells in serum-free medium after twelve hours 
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Fig. 3.26 Cytotoxicity of free OOX, Uposome formulations ofDOX and empty Uposome 
(fonnulation I without DOX) against Hela ceUs in complete medium after three hours of 
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Fig. 3.27 Cytotoxicity of free DOX. liposome fonnulations of OOX and empty liposome 
(formulation I without OOX) against Hela cells in complete medium after twelve hours 
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Fig. 328 Cytotoxicity of free DOX and liposome fonnulations of OOX 
against DOX concentrations (OJ, 1, 10 (.lglmL) in Bl6Fl0 cells at pH 6.0 in 
serum free media after 12 hours of incubation. *Average values of percent ceU 
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DOX concentrations (0.1, 1, 10 Jl&"mL) in Hela cells at pH 6.0 1~ ~~ 




3.24 Cellular uptake of free DOX and li.,Osomal DOX. Based on the cytotoxicity 
results of the previous section, the uptake of pH-convertible formulation II and control 
liposome by B 16F I 0 cells was characterized by flow cytometric analysis of the 
fluorescence of the cargo drug doxorubicin. Free DOX was employed as the positive 
control. A detachin solution (Genlantis, San Diego, CA) was used to detach cells as the 
detachin is much milder than the trypsin for detachment and centrifugation of cells. The 
time of incubation of the fonnations with the ceJis is critical as high time points result in 
the high cell kill and which results in poor analysis ofthe OOX uptake by cells. On the 
other hand a very short time may not result in sufficient formulation uptake by the cells. 
After optimization, 4 hours of incubation was elected for the uptake stud.ies. 
The flow cytometry data (Fig 3.30, 3.31) indicate that the change in mean fluorescent 
intensity of cells incubated by controlliposome was not significant between pH 7.4 and 
pH 6.0. In contrast, the average fluorescence values for liposome II show an increase of 
57% at pH 6.0 compared to pH7.4. This clearly indicates higher OOX uptake by cells at 
lowered pH owing to the increased interaction between the cells and the newly turned 
cationic liposome n. 
It is also interesting to note that the uptake of free DOX infact decreased at lowered pH, 
which might be due to higher proportion of charged DOX molecules at low pH with 
doxorubicin being a weakly basic drug. However, this small decrease did not trans1ate to 
lower cytotoxicity of free OOX at pH 6.0 
Our strategy to fonnulate doxorubicin in pH tunable liposomes insulates doxorubicin 
from the low pH microenvironment and yet exploits the acidic microenvironment for the 
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increase in the surface charge of the liposomes and subsequent greater interaction with 
cancer cells. 
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Fig. 3.31 Mean fluorescent intensity ofB16FIOceUs treated with free OOX or liposomal 
DQX by flo\.vcytometry. 
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Cbapter4: .Summary and Conclusion 
Lippsomal ~liug delivery system that can encapsulate and deliver anticancer agents ·was 
developed in our studies. Al_l ideal anticancer (jelivery system has primarily four 
requirements; (l J selectivity to c$cer (2) efficient delivery ofanticancer agent inside the 
cancer cells (3) stability of the liposome formulation ( 4) high blood circulation half life~ 
To achieve. these goals. two strategies wer~ employed. 
Firstly. a pH-sensitive Iiposome was envisaged by incorporating a pH~sensitive 
PEGy!ated lipid that can hydrolyze at low pH tumor environment. The hydrolysis at 
mildly acidiC tun1or cortdidons was envisioned to be exploited by placing a hydrazone 
linker between the PEG head group and hydrocarbon chains of the PEGyJated lipid. The 
shedding of PEG coating would expose positive charges and would result in greater 
tumor interaction. The .synthesis of the hyd,rqzone-b~sed pH•sensitive lipid revealed that 
the iipid hydrolyzes even at a neutral pH and was riot highly stable at physiological pH. 
TberefQre, such approach would not be a good choice for developing a phannaceuticaiJy 
viable drug delivery system. 
To achieve the aforementioned goals; we changed the strategy .to desi~ing a pH-
convertible liposome with more stable imidazole-based lipids. The design principal 
works on the basis of acquisition .of positive charges by protonation of the imidazole 
moiety rather than hydrolysis. Such protonation strategy renders better formulation than 
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· previously reponed acid-labile Jiposomes owing to its better· stability on shelf; 
Additionally, the PEG coating on the surface of the convertible liposomes is also 
clustered upon exposure to mildly acidic pH as seen. in tumor interstitium due to 
electrostatic and vander waalmteraction between the protonated imidazole lipids and .the 
negatively charged PEGyJated lipid. 
We have used do:x:orubiciJ~ as the liposome cargo to study the cytotox.icity and cellular 
uptake of these liposomes. DOX ·acts both as an anticancer age(lt ·encapsl.lhite4 in the 
liposome and also as a fluorescent marker ofintracellular uptake of this. Jiposomal system 
using flow .cytometty. The encapsulation and retention of our model drug doxorubicin 
was enhanced· by using a previously reported manganese sulfate remote loading approach 
(101). 
Our cytotoxic studies indica,te the increase of cytotoxicity at pH 6.0 in all · the pH· 
convertible liposomes compared to pH 7A in t\VO caric¢r cell lines (B 16 FlO and Hela). 
Furthermore, the formulation (II) show significantly higher l!ptake in the B t6F 1 0 cells at 
lower pH. The anticancer cytotoxicities of the pH-convertible lip()somes are better than 
the control PEGylated Iiposomes which .werereported to·haveminiinum interaction with 
the cancer cells and rely mostly on ·the slow release of drug from the fotinulation~ which 
can be suboptimal to etlicieJtdy'ldlhhe cancer cells. The slow release· of doxoi'ubidn and 
many other anticancer dnigs for a su~ined period can induce the: pr.eviously mentioned 
'multi-drug resistance' and thereby further reducing the efficacy ofthe formulation. 
Our studies ·supports the approach of ¢xploiting the lower pH in tumotal inte~titium by 
carefuLchoice of lipids in the design ofliposomes thatinteract more strongly witlt cancer 
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cells in response to lowered pH. Another potential advantage ofthi.S liposomal delivery 
system would be its Jower cost because its lipid components are .either inexpensive or can 
be conveniently synthesized. 
It is interesting to note-that while increasing the pKa of the imidazole lipid does increase 
the cytotoxic effect of the formulation, it also increases the interaction of these systems 
with negatively charged model lipoS<>mes at the physiological pH. It remains to be 
explored whether the increase in pKa of the imidazole Jipid in the liposomal fonnulation 
would cause higher interactio[lwith components of blood in circu1ation, 
Itis alsooimportant to notethatthe proposed liposome formulation will find:limitation in 
patients with conditions ofmetabolic acidosis which rnay arise ·dUe tO dysfunction of liver 
(lactic acidosis), kidney or lung (hypoventilation). The resultant decrease in blood pH 
under such clinical situations may trigger premature display of positive charges by the 
liposomes and subsequently their excessive Clearance from the blood~ by RES. 
131 
References 
1. Cancer facts and figures 2013. American cancer society, Atlanta, 2013~ 
2. http:l/www .cancer.gov/cancertopics/cancerJ ibrary/what-is..cancer 
3. http://globocan.iarc.fr/factsheetslpopulations/factsheet.asp?uno=900 
4. Cancer statistics 2009, American cancer society, Atlanta, 2009. 
5. William E. Luttrell~ Warren W. Jederberg. Kenneth R. Still. ·roxicology 
Principles for the Indu.~trial Hygieni.!.'f; AlHA, 2008 
·6, http:/lwww.iarc.fr/enlpublications/pdfs-online/epilcancerepi/CancerEpi-l.pdf 
7. Gisele M. Hodges, Charles Rowlatt. Developmental Biology and Cancer, CRC 
Press, 1994 · 
8. Geoffrey M. Cooper. Elements of HUman Cancer; Jones & Bartlett Learning, 
1992 
9. Allen tM, Ligand-Targeted Therapeutics In Anticancer Therapy~ Nature Reviews 
Cancer, 2002,2, (10), 750-63 
10. Chatelut, Etienne;: Delord, Jean~Pierre; Canal, Pierre., Investigational New Drugs 
2003y 21; (2), 141-148 
11. Yao, X in; Panichpisal, Kessarin; Kurtzman, NeH; Nugent. Kenneth, The American 
Journal oft he Medical .Sceincest 2007 ~ 3 34, (2)J l J 5·!24 
12. Pfeffer, Brad;· Tziros, Constantine; Katz J, Richard, Current concepts of 
anthracycline cardiotoxicity: pathogenesis, diagnosis and prevention, British 
Journal ofCardio/ogy, 2009, 16t (2), 85 ... 89. 
132 
l 3. Hock~I. Michael; Vaupel, Peter, Tumor Hypoxia: Definitions and Current 
Clinical, Biologic,. and Molecular Aspects, Journal of the National Cancer 
Institute, 2001,93, (4), 266~276. . 
14. Partridge, Ann H.; J. Burstein, Harold~ Winer; Eric P. Side Etr.ects of 
Chemotherapy and Combined Chemohonnonat Therapy in Women With Early-
Stage Breast Cancer, Journalofthe National Cancer Institute Monographs, 2001, 
(30), 135-42. 
15. Singh, J>.; Singh, A., Ocular adverse effects of anti~ancer chemotherapy and 
targeted therapy~ Journal of Cancer· Therapeutics and Research, 2012. 
16. Fabbrocini, G.; Cameli, N.; Romano, MC; Mariano, M.; Panariello, L.; Bianca, 
D.; Monfrecola, G., Chemotherapy and skin reactions, JournalofExperimenlal & 
Clinical Cancer Research, 20l2; 31, (50), 1·6. 
17; Bentzen SM., Preventing or reducing late side ef(ects of radiation therapy: 
radiobio1ogy meets molecular pathology, Nalure Reviews Canc.er, 20<>6, 6, (9),. 
702~713. . 
18.Kim; WY; Oh1: SH; Woo, JK; Hong, WK~ Lee, HY., Targeting heatshock protein 
90 .overrides the resistance of Jung cancer cells by blocldng radiation-induced 
stabil~atioil of hypoxia-inducible factor-1afpha, Cancer Re.fearch, 2009, 69, (4), 
162~32. 
I 9. http://www ,cancer.gov/cancertopic,S/factsheet/Therapy/biological 
20. http://training.seer.canct!r.gov/treatmentlbiotherapy/sideeffects.html 
2·1. Hoag, JB; Azizi, A; Doherty; TJ; Lu, 1; Willis, RE~ Lund, ME., Association of 
cetuximab with adverse pulmonary event$ in cancer. patients: a comprehensive· 
review,Joumal.ofExperimental &Clinical Cancer .Research. 2009, 28~(113). 
22. Hanson, ED; Hurley, BF; Intervening .on the side effects of honnone-dependent 
cancer treatment: the role of sn-ength training,. Journal of aging research, 2011, 
903291 . 
23. Kumar, RJ.; Barqawi, AI; Crawford, David E~; Adverse Events Associated With 





25. Bosslet ·~Straub R, Blumrich M, Czech J, Gerken M. Sperker B, Kroemer 
HK,Gesson.JP, Koch M~ Monneret C ... Elucidation of the· mechanism -enabling 
tumor selectrve prodrug monotherapy, Cancer research, 1998, 5·8, (6), 1195-201 
26. R. Srinivasan, Nanotechnology for Cancer Therapy, Cyber Tech Publications, 
2008 
27. Gottesman, M. M.; Fojo. T.; Bates, S. E., Multidrug ~istance in cancer: Role of 
A TP-dependent transporters, Nature Reviews Cancer, 2002. 2, {l). 48- 58 
28. Peer, D; Karp, JM; Hong, S; Farokhzad, OC; Margalit, R; Langer R, Nanocarriers 
as an emerging platform for cancer therapy, Nature Nanotec:hno/ogy, 2007, 2. 
(12), 751-760 
29. Allen TM, Ligand-Targeted Therapeutics In Anticancer Therapy, Nature Revicil·s 
Cancer,2002, 2, (1.0), 750·63 •. 
30.Adams, GP; Schier, R; McCall, AM; Simmons, HH;Horak. EM; Alpaugh. 
RK~ Marks, JD; Weiner, LM; High affinity restricts the localization and tumor 
penetration ofsingJe-chain fv antibody molecules, Cancer Research, 2001, 61, 
(12), 4750-4755. 
31. Tolcher, Anthony W.; Sugarman, ·Steven; GeJmon. Karen A.; Cohen, Roger; 
Saleh, Mansoor; Isaacs, Claudine; Young, Leslie; Healey, Diane; Onetto, Nicole; 
SJichenmyer, William, Randomized Phase- II Study of BR96-Doxorubicin 
Conjugate in Patients With. Metastatic Breast Cancer~ Journal of CHnh.·al 
Oncology, 1999, 17~ (2), 478-484 
32. Napier, MP; Shanna, SK; Springer, CJ; Bagshawe, KD; Gr.een, AJ; Man in. 
J; Stribbling, · SM; Cushen, N; O'Malley, D; Begent, RH. Antibody-directed 
enzyme prodrug therapy: efficacy and mechanism -of action in colorcctal 
carcinoma, Clinical Cancer Re.~earch, 2000.6, (3), 765~772 
33. Hovork~ 0; St'astny. M;Etrycb, T; Subr,. V; Strohalm, J; Ulbrkh, K;Rihov~. !3· 
Differences in the intracellular fate of free and pelyrner-bound doxorubtcm. 
Journal ofControlled Release~ 2002~ 80, (t-3), 101-117 
134 
34. Satchi, R; Connors, TA; Duncan, R PDEPT: polymer-directed enzyme prodrug 
therapy,Britb;h Journal of Cancer (200 1) 85{7), 1070-1076 
35. lmmordino. Maria laura; Dosio. Franco; Cattel, Luigi, Stealth Hposomes-: 
review of the basic science, rationale, and clinical applications, .existing and 
potential, lnternationalJourna/ofNimomedidne, 2006, 1,(3) 297-315 
36. Scherphof, G. L.; Dijkstra, J.; Spanjer~ H. H.; Derksen, J. T. P.; Roerdink, ·F. H., 
Uptake and intracellular· processing of targeted and nontargeted Jiposomcs by rat 
Kupffer cells in vivo and in vitro; Annals of the New York Academy ofSdence.~. 
1985, 446, 368-84. 
37. Philippot, Jean R.; Schube, Francis. Lipo.mmes As Tools in Basic Re.vec~r<·h cmd 
Industry, CRC .Pr.ess, 1994, 181 
38. Chonn, A; Cums, PR; Devine, DV, The role of surface charge in the activation of 
the classical and alternative pathways of complement by Jiposomes. Journal of 
Immunology, 1991, 146, (12), 4234-41 . · 
39. Philippot, Jean R.; Schube~ Francis. Liposomes As Tools in Basic Research and 
Industry, CRC Press, 1994, 181 
40. CuHis, PR; Chonn, A; Semple. SC, Interactions of liposomes and lipid-based 
carrier systems with blood proteins: Relation to clearance behaviour in vivo, 
AdvancedDrug DeliveryReview&";l998 32,{1-2), 3-1.7 
4 t. Senior, J; Trimble, K.R.; Maskiewicz, R., Interaction of positively-charged 
liposomes with blood: Implications for their application in vivo, Biochimica et 
BiophysicaAc:ta, 1991, )(}70,(1)~ 173- 179. 
42. Oku, N.; Tokudome, Y.; Namba, Y.; Saito. N.; Endo; M.; Hasegawa. Y.; Kawai, 
M·.; Tsukaday H.;, Okada, S., Effect of· serum protein binding on real-time 
trafficking of Jiposomes with different charges analyzed by positron emission 
tomograpgy, Biochimica et Biophysica A·cta, 1996, 1280, (l), 149-154 
43. Hong, RL; Hoang, CJ; Tseng, YL; Pang. VF; Chen, ST; Liu, JJ; Chang, FH, 
Direct comparison of liposornal doxorubicin with or without polyethylene glycol 
coating in C~26 tumor~bearing mice: is surface coating with polyethylene glycol 
beneficial?~ ClinicalCancer Research, 1999, S, (1), 3645-3652 
135 
44. Parr, MJ; Masin. D; Cullis, PR; Bally, MB, Accumulation of Liposomat Lipid and 
Encapsulated Doxorul>iCin in Murine Lewis Lung Carcinoma: The Lack of 
Beneficial Effects by Coating Liposomes with Poly(ethylene. glycol), The Journal 
o.f Pharmacology and Experimental Therapeutics, 1997. 280, (3). 1319-1327. 
45 .. Daleke, D. L; Hong. K.; Papahadjopoulos, D .•. Endocytosis of Jiposomes by 
macrophages: bind.ing, acidification and leakage ofliposomes monitored by a new 
fluorescence assay~ Bio(:himicaetBiophysica Acta, ]990, 1024, (2), 352~366 
46. Du, H; Chandaroy, P; Hui, SW., Grafted poly-( ethylene gly.col) on lipid surfaces 
inhibits protein adsorption and cell adhesion, Biochimica et Biophy.~it.:a Acta, 
1997~ 1326, (2), 236-248 
47. Huang, SL; MacDonald, RC., Acoustically active liposomes for drug 
encapsulation and ultrasound-triggered release, Biochimica et JJiop!iysica Acta, 
2004. 1665, {1-2), 134 - 141. 
48. Rapoport N~, Combined cancer therapy by micellar-encapsu1ated drug and 
ultrasound, International Journal ofPharmacetilics. 2004.277. (1-2), 155-162 
49. Leung, SJ; Romanowski, M., Light·Activated Content Release from Liposomes 
Theranostics. 2012. 2(1 0), 1020-1036 
50. Pidgeo~ C; Hun~ CA., Light sensitive liposomes, Photochemistry and 
Photobiology, 1983, 37, (5), 491 -494. 
51. Ohya, Y; Okuyama. Y; Fukunaga, A; Ouchi, T., Photo-sensitive lipid membrane 
perturbation by a single chain lipid having tenninal spiropyran group. 
Supramolecular Science, 1998, s. {l-2}. 21-29. 
52. Anderson, VC; Thompson, DH., Triggered release of hydrophilic agents from 
plasmalogen liposomes using visible light or acid. Biochimica et Biophysica Acta, 
1992, 1109, (1).33-42. 
53. Wan. Y; Angleson, JK; Kutateladze, AG., Liposomes from navel photola-bile 
phospholipids:. Light-induced unloading of small molecules as monitored by PFG 
NMR, Journal of American Chemical Society,200Z, 124~ (20)~ 5610-5611.. 
54. Li~ Z; Wan, Y; Kutateladze, AG., Dithiane-based photolabiJeam.;phiphiles: toward 
photolabile liposomes, Langmuir, 2003, 19~ (16), 6381...-6391. 
136 
55. Zhang, ZY; Smith, BD., Synthesis and characterization ofNVOC-DOPE, a caged 
photoactivatable derivative of dioleoylphosphatidylethanolamine. Bioconjugate 
Chemistry, 1999; 10, (6), 1150•1152. 
56. o·~~i~n, DF; .Annitage; B; Benedicto, A; Bennett, DE; Lamparski, HG; Lee, YS; 
Snsm, W; S1sson, TM., Polymerization of preformed self-organized assemblies 
AccountsofChemicalResearch, 1998,31, (12), 861-868. 
51. Gerasimov, OV; Boomer, JA; Qualls, MM; Thompson, DH., Cytosolic -drug 
delivery using . pH- and light•sensitive liposomes, Advanced Drug Delivery 
Reviews, 1998, 3~. (3), 317-338 
58. Yatvin, M~B; Weinstein~ J.N; Dennis, W~H; Blumenthal, R., Design of Hpos.omes 
for enhanced local release of drugs by hyperthermia, 1978, Science 202, ( 43 74) 
1290-1293 
59. Ta, T; Porter, TM., Thennosensitive Jiposomes for localized delivery and 
triggered release· of chemotherapy~ Journalofcontrolled release. 2013, 169~ (I -2), 
112-125 
60. Borchman, D; Yappert, M C., ,Lipids and the ocular Jens. The Journal of Lipid 
Research, 2010, 51, (9). 2473-2488 · 
61. Gaber, M.H; Hong, K.; Huang, S.K.; Papabadjopoufos, D.. Thermosensitive 
sterically stabilized liposornes: fonnulation and in vitro studies on mechanism of 
doxorubicin release by bovine serum and humal1 plasma, Pharmaceutical 
research, 1995, 12 (10), 1407-1416 
62. Meshorer, A.; Prionas, S.D.; Fajardo, L.F.; Meyer, J.L.; Hahn, G,M.; Martinez, 
A.A., The effects of hyperthermia on nonnal mesenchymal tissues: application of 
a histologic grading ~ystem, Archives of Pathology and Laboratory MedU.:ine, 
1983. 107, (6), 328-334 
63. Anyarambhatla, G.R.; Needham. D., Enhancement of the phase transition 
permeability of DPPC liposomes- by incorporati"on ofMPPC: a new temperature· 
sensitive liposome for use with mild hyperthermia, Journal of Liposome 
Research, 1999,9, (4), 491-506 
64. Needham, D.; Anyarambhatla, G.;Kong, G.; Dewhirst, M.W., Anewtemperature 
sensitive liposome for use with mild hyperthermia: characterization and testing in 
a human tumor xenograft model, Cancer Research, 2000, 60, (5). 1197-1201 
137 
65. Banno; B.; ICkenstein. L.M.; Chiu, G.N.; Ba11y~ M.R; Thewalt, ~ .; Brief, E.; 
Wasan, E.K., Th~ functional roles ofpoly(ethylene glycol)-lipid and lysolipid in 
the .drug retention . and release from lysolipid-containing thennosensitive 
liposomes in vitro· and in vivo, Journal of Phannaccuticalsciences 2010 99 (5) 
2295-2308 ' ' ' 
66. Sandstrom, M.C.; Ickenstein, L.M.; Mayer, L.D.; Edwards, K ., Effects of lipid 
segregation and ·lysOiipid dissociation. on drug · re"Jease from thennosensitive. 
liposomes,JournalofControlled Release, 2005. 107, (l), Jj}-142 · . · .. 
67.Hauck, M:L.; LaRue, S.M.-; Petros, W.P.; Poulson, J.M.; Yu, D.; Spasojevic~ I.; 
J>ruitt, A.F.; Klein, A.;. Case, B.; Thrall, D.E.; Needham, D.; Dewhirst, M.W., 
Phase I trial of doxorubicin-containing low temperature sensitive liposomes in 
spontaneo~as canine tumors, Clinical Cancer· Research, 2006• 12, ( 13), 4004-
4010. 
68. Amstad, E.;, Kuhlbrecher, J.;, MQJler, E.; Schweizer, T.; Textor, M.; ReimhuJt, E.; 
Triggered release from lipoS9mes through magnetic actuation of iron oxide 
nanopartide containing membranes, Nano Letter.~, 2lH l, I 1, (4), 1664-1670 
69. Babincova, M.; Cicmanec, P.; Altanerova, V.; Altan~r,. C.; J)abincc, P., AC· 
magnetic field controlJed drug release frortt magnetoliposomes: design of a 
method for· site-specific· chemotherapy. Bloelectrochemistry, 2002, 55, ( 1-2), 17-
19 
70. Nubuto~ H.; Sugita, T.; Kubo, T.; Shimose, S.; Yasunaga, Y~; Murakami, T.; Ochi 
M., Evaluation of systemic chemotherapy with magnetic lipo~mal doxorubicin 
an(i a dipole external electromagnet, lnternationaljournul of Cancer, 2004, 109, 
(4), 627-635 
71. KU:bo, T.; Sugi~. T.; Shimose, S.; Nitta, Y.; lkuta, Y.; Murakami, T., Targeted 
systemic chemotherapy using magnetic liposomes with incorporated adriamycin 
for osteosarcoma :in hamsters, International Journal of-Oncology, 200l, 18, (l), 
121- 125 
72. Babincova, .M.; Altanero:va, V.; Lampert, M.; Altaner, C.; Machova, E.; Sramka, 
M.; Babinect P~, Site-specific. j~ vivo targeting of magnetoliposomes using 
exterJ)ally .applied magnetic field~ Z. Naturforsch C., 2000, 55. (3-4)i 278--281 
73. Jain,S.; M·is~ V.; Singh. P;; Dubey, PK,; Saraf, OK.; Vyas, SP., R_GD-anch~red 
magnetic liposomes for monocytes/neutrophils-mediated bram targetmg, 
/nternationalJournalof Pharmaceutics, 2003t 261, ( 1·2) 43-5 5 
138 
74. Mats~n~ga, T.; f!igashi, Y.: Tsuj~mura, N., Drug delivery by magnetoliposomes 
contatnmg bactertal magnettc partacles. Cell Engineering. 19"97, 2, 7-l t 
75. Saiy.ed, ZM.; Telang~ SD.; Ramchand, CN., Application of magnetic techniques 
in the field of drug discov«=ry and biomedicine, BioMagneric: Rt:.w!ardl and 
Technology, 2003~ 1, (1},2 
76. Cordes •. E. H.; Bull, H.G., Mechanism and. catalysis for hydrolysis of acetaJs. 
ketals, and ortho esters. Chemical Reviews, 1974, 74, {5), 581-603 
77. Song, Jie; Hol1ingsworth, R. 1., Synthesis, ·Conformational Analysis. and Phase 
Characterization ofa Versatile Self-Assembling Monogluco~yJ Diacylglycerol 
Analog, Journal of American Chemical Society, 1999, 1 21, (9), t 851-186 J 
78. Asokan, A.; Cho, MJ.; CytosoHc· delivery of macromolecules. 3. Synthesis and 
characterization of acid~sensitive his-detergents, Bioc:onjugate Chemistry. 2004. 
15t (6). 1166-1173 
79.Shin, J.; Shum, P.; Thompson, DH., Acid;.triggered release via dePEGylation of 
DOPE liposomes containing acid.:tabile vinyl ether PEG-lipids, Journal t~/ 
Controlled Release, 2003,91, (1-2), 187-200 
80. Rui, Y ., Wang, S., Low, P.S., and Thompson. O.H., Diplasmenylcholine-folate 
Uposomes: an efficient vehicle for intracellular drug delivery, JAm Cllem Soc 
1998, 120, (44), 112f3-ll218 
81. Chen, H.; Zhang, H.; McCallum, CM.; Szoka, FC.; Guo, X., Unsaturated cationic 
ortho esters for endosome penneation in gene delivery, Journal of Medicinal 
Chemistry, 2007, 50, (18), 42.69-4278 
82. Bergstrand N, Arfvidsson MC, Kim JM, Thompson DH, Edwards K., -Interactions 
between pH-sensitive Iiposomes and model membranes, Biophysical Chemistry, 
2003, 104, (1), 361-379 
83. Guo, X.; Szoka, FC Jr., Steric stabilization of fusogenic liposomes by a low-pH 
sensitive PEG-diortho ester--lipid conjugate, Bioconjugate Chemistry, 2001, 12, 
(2),291-lOO 
84. Masson, .C.; Garinot, M.; Mignet, N.; Wetzer, B.; Mailhe, P.; Scherman. 






















potential tools for nonviral gene delivery. Journal ofC(mfro!led Release, 2004. 
99; (3)~ 423 - 434 
85. Vance, JE.; Steenbergen, R.~ Metabolism and functions of phosphatidylserine. 
Progress in LipidResearch.2005, 44, (4), 207-234 
86. Mounkesy LC,; Zhong, W.; Cipres-Palacin, G.; Heath, TD.; Debs, RJ .• 
Proteoglycans mediate cationic liposome-DNA comple~-based. gene delivery in 
vitro and in vivo; The Journal ofBiological Chemistry~ 1998, 273, (40). 26164-
26170 
87. Mislick~ KA.; B.aldeschwieler, JD., Evidence. for the role of proteoglycans in 
cation-mediated gene transfer, Proceeding.-; ofthe Natir>nul Academy af Science.+;. 
l996, 93, (22), 12349-12354 
88. Szacbowicz-PeteJska, B.; Dobrzynska, 1.; Figaszewski, Z.; Sulkowski, S .• 
·Changes in physico-chemical properties of human large intestine tumour cells 
membrane, Molecular and Cellular Biochemistry, 2002~ 23&, (1-2)~ 41-47 
89. Stakacs, G.; Paterson~ JK.; Ludwig, JA.; Booth-Genthe, C .; Gottesman MM.t 
Targeting multidrug resistance in cancer, Nature Reviews Drug Discovery, 2006, 
5, (3}, 219-234 
90. lmmordino, ML; Dosio, F.; Cattel, L., Stealth liposomes: review of the basic 
science, rationale, and clinical applications, existing and potential, International 
Journal of Nanomedicine, 2006, l, (3), 297-3 15 
91. Kale, AA.; Torchifin, VP., Design,. synthesis, and characterization of pH-sensitive 
PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect 
ofsubstitutes at the hydrazone linkage on the pH stability of PEG-PEconjugates, 
BioconjugateChemistry,2001, 18, (2), 363-370 
92. The Association of BritisbPhannaceutical Industry, London, UK 





95. Aissaoul A., Martin B~; Kan E.; Oudrhiri N.; Hauchecome M.; Vigneron, JP.; 
Lehn, JM,; and Lehn P., Novel Cationic Lipids rncorporating an ACid-Sensitive 
Acylhydrazone Linker: Synthesis and Transfection Properties; Journal of 
Medicinal-Chemistry, 2004,47, (21), .S2JOa5223 
96; Marik, .J.; Tartis, MS.; Zhang~ H.; Fung, JY.; Kheirolomoom, A.; Sutcliffe, 
JL.; Ferrara~ KW., Long-drcul::tting liposomes radiolabeled with 
e8FJ.tluorodipalmitin ([ 111FJFDP), Nuclear Medicine and Biology, 2007, 34~ (2), 
165'-171 
97. Stamatova, SD.; Stawinski, J., A Simple and Efficient Method for Direct 
A~ylation of Acetals with Long Alkyl~Chain Carboxylic Acid Anhydrides, 
Tetrahedron, 56, (49), 9679..;9703 
98. Torchilin, V.; Weissig, V., Liposomes: A Practical Approach 2003, 4-7, Oxford 
University Press 
99. Haran, G~; Cohen, R.; Bar, L. K.; Barenholz, Y., Transmembrane ammonium 
sulfate gradients in 1iposomes produce eflkient and su.bte entrapment of 
amphipathic we~ bases. Biochimica et Biophysica Acta I 993, ll Sl, {2), 20 t -15 
100. Bolotin, E. M.; Cohen, R.; Bar, L.K.; Emanuel, N.; Ninio, S.; Lasic, D.O.; 
Barenholz, Y., Ammonium suJfate gradients for efficient and stable remote 
loading of amphipathic w:eak bases into lip<)somes and ligandoliposomes. Journal 
ofLipost;~me Re~4tearch, 1994', 4, (1), 455-479 
1 OL Cheung, BC.; Sun, TH.; .Leenhouts, JM;; Cullis, PR., L(>ading of doxorubicin 
into liposomes by forming Mn2+ -drug complexes, Biochiinica et Biophysica acta, 
1998, 14-14, (1·2), 205-216 
l02.Huwy1er, J.; Di'ewe,J.; Krahenbuhl, S., Tumor targeting using Jiposomal 
antineoplastic drugs, lliternationatJoumal of Nanomedicine, 2008, 3, (1 ), 21- 29 
lOJ. Gabizori, M., Stealth Liposomes and Tumor Targeting: One Step further in the 
Quest for the Magic Builet, Clinical Cancer Reseqrch, 2001,7, (2), 223- 225 
104. Romberg. B.; Hennink, WE.; Storm, G.; Sheddable Coatings for· Long-













l 05. Danhierr F~; Feronb, 0 .; Preat, V., To exploit the tumor· microenvironment: 
Passive. and active tumor targeting .of nanocarriers for anti-cancer drug delivery, 
J(iurnal of Controlled Relea:'ie, -2010, 148~ (2), 135-146 
106.1essi, E.; Marino. ML.; Lozupone, F.; Fais, S.; Milito, AD~; Tumor acidity and 
(rlalignancy: novel aspectsin .the -design of anti-tumor therapy; Cancer Therapy. 
2008,6,55-66 . 
107. Vaupe~ P.; Kallinowski, F.; Okun·ieff, P .• Blood flow. oxygen and nutrient 
supply, and metabolic microenvironment of human tumors: a review. Cam·er 
Research, 1989~ 49 •. (23), 6449-65 
108. Tannock, lF.; Roiin, D., Acid pH in Tumors and Its Potential for Therapeutic 
Exploitation, Cancer Research, 198·9, 49, (16), 4373--4384 
109~ Song, CW.; Griffin, R.; Park, HJ., Influence of Tumor pH oil Therapeutic 
Response, Cancer Drug Discovery and Development, 2006,21-42 
llO. Svastovi, E.; Hulikov8, A.; R~fajova, M.; Zat•ovicova, M.; .Gibadulinovli, 
A.; Casini, A.; Cecchi, A~; Scozzafava, A.; Supuran, CT. ~ Pastorek, 
J~; Pastorekova, S .• Hypoxia activates the capacity of tumor-associated carbonic 
anhydrase IX to acidifY extracellular pJ-(, FEBSLetters., 2004, 577,.(3), 439--45 
I 11. Needham, D.; Dewhirst, MW., The development and testing of a new 
temperature-sensitive drug delivery system for the treatment of solid tumors, 
Advancedbrug~livery Reviews, 2001,53, (3), 285-305 
112. Demakov~ MY.; Sudarikov, DV.; Rubtsova, SA.; Slepukhin, PA.; Kuchin, 
AV; Synthesis of neomenthylsulfanylirrtidazoles, Chemistry of Natural 
Compounds.,20l2, 47, (6), 899·902 
U3. Oemakova, MY.; Sudarikov, DV;; Rubtsova, SA.; ·frolova, LL.~ Popov, AV.; 
S1epukhin, PA.; Kuchm, AV., .Synthesis- and Asymmetric Oxidation of 
(Caranylsulfanyl)-lH-imidazoles, Helvetica Chimica Acta, 2012, 95(6), 940-950 
114. Singh, RS~; Gon~alves, C.; Sandrip, P.; Pichon, C.; Midoux, P.; Chaudhuri, A., 
On the Gene Delivery Efficacies of pH-Sensitiye Cationic Lipids via Endosomal 










1 lS.Ravi, MNK.; Bakowsky, U.; Lehr, CM., Preparation and character~alion of 
cationic PLGA nanospheres as DNA carrierS, Biomaterials, 2004, 25, (I 0), 
1771-1777 
116. Budkert V.; Gurevich, V.; Hagstrom, JE.; Bonzov, F.; Wolff, JA., pH·sensitive, 
cationic liposomes: a new synthetic virus-Jike vector, Nature Biotechnology, 
1996, "14, {6), 760-764 . 
117. Gao, H.; Hui, KM., Synthesis·of a novel series of cationic lipids thatcan act as 
efficient gene delivery vehicles through systematic .heteroeyclic substitution of 
cholesterol derivatives, Gene Therapy, 2001, 8, (11 ), 855~863 
J 18~ Chen,. H~;Zhang, H.; McCallum, CM.; Szoka, FC.; Guo, X., Unsaturated 
Cationic Ortho Esters for Endosome Penneation in Gene Delivery, iournal of 
Medicinc{/Chemistry. 2007, 50, (18), 4269-4278 
I J 9'. BetgStiand, N.: Arfvidsson, MC.; Kim, JM.; Thompson~ DH.~ Edwards, K., 
Interactions between pH-sensitive lip<>somes and mooef membranes. 
Biophysical Chemistry, 2003" I 04~ (1 ), 361·379 
120~ Mabrey, S.; Sturtevant, JM., Investigation of pha<ie transitions of lipids and lipid 
mixtures by high sensitivity differential Scanning calorimetry, Proceedings of 
the national Academy of SCiences ofthe USA, l976r 73, (.1 1),.3862-3866 
121. Wolf: DE., Lipid domains: The parable·ofthe blind men and the: elephant, 
Commu1l. Molec. andCe/L Biophys, 1992,8, 83-95. 
122. Cheung, .BC.; Sun, TIL; L~enhouts, JM.; Collis, PR., Loading of doxorubicin 
into liposomes by fonning Mn2• ·drug .complexes, Bioch;mica et Biophysica 
acta~ 1998,1414, (1-2), 205·216 
123. Miller, CR~;.Bondurant, B.; McLean, SO.; McGovern, KA., Liposome-Cell 
Interactions in 'Vitro: Effect of Liposome Surface Charge on the Binding and 
E11docytosis of Conventional and Sterically Stabilized LiPQsomes. 
Biochemistry, 1998, 37, (37), 12.875-12883 
124. J(.arve, S.;Aiaouie, A.; Zhou, Y.;Rotolo, J.; Sofou. S., The use of pH-triggered 
leaky heterogeneitie~ on rigid lipid bilayersto improve intracellular trafficking 
and · therapeutic potential of targeted liposomal immunochemotherapy, 

















































125.Amselem~ S.; Gabizon, A,; Barenhol~ Y.~ Optimization and upscaling of 
doxorubicin-containing Jiposomes. for .clinica1 use; Journal of Pharmaceutical 
Sciences~ 1990, 79, (12)~ 1045-1052 
126. Zimmer. A.; Aziz, SA.; Gilbert, M.; Werner, D.; Noe, CR.. Synthesis of 
cholesterol modified cationic lipids for lipbsomal drug delivery of antisense 
o1igonuc1eotides, European journal of pharmaceutics and biopharnwceutics, 
1999-,47, (2), 175- 178 
127. Guo, X.; MacKay~ JA; Szoka,c Jr, FC,~ Mechanism ofpH~Triggered Collapse of 
Phosphatidylethanolamine Liposomes Stabilized by an OrthO Ester 
Polyethyleneglycol Lipid, Biophysical Journal, 2003~ 84.(l), 1784--1795 
128. http://www.bme.umich~edullabs/centlab/researchloverview .php 
129. Koyama, . TM.; Stevens, CR.; Borda, EJ.; Grobe, KJ.; Cleary. DA .• 
Characterizing the Gel to Liquid Crystal Transition in Lipid-Bilayer Model 
Systems, TheChemica!Educator, 5, (3), S1430-4171(99) 01273-t 
130. Bhatnagar, A.; Sharma, PK.; Kumar. N., A Review <m "lmid.azolcs'': Their 
Chemistry and Pharmacological Potentials, lnternationatJournul of PhcmnTech 
Research, 20 11, 3, (1 ), 268-282 
